[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Mc3 Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":214},{"warningLetters":4,"total":213},[5,32,54,80,101,123,144,160,181,197],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},2677,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-05-10T13:20:00Z\">05\u002F10\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-21T04:00:00Z\">04\u002F21\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcaco-ltd-624606-04212022\">MCACO, LTD\u003C\u002Fa>","Division of Human and Animal Food Operations West III","CGMP\u002FDietary Supplement\u002FAdulterated\u003Cbr \u002F>\r\n","","CGMP\u002FDietary Supplement\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Erik Aguayo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MCACO, LTD\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1610 W. Polo Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grand Prairie\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75052\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nApril 21, 2022\u003C\u002Fp>\n\n\u003Cp>Ref: CMS # 624606\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Aguayo,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 1610 W. Polo Rd, Grand Prairie, TX from November 4, 2021, through December 7, 2021. Based on the inspectional findings we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility revealed serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations, Part 111 (21 CFR 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. FDA acknowledges the receipt of your e-mail correspondence dated December 30, 2021, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>The significant violations documented during the inspection include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, your finished product specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> fail to include established specifications for purity, strength, and composition for the dietary supplement products. When establishing such specifications, a list of tests or references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges, or other criteria for the tests described should be included.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your response, received December 30, 2021, which acknowledged that specific elements needed to be updated and asserted that “[b]y March 31, 2022, MCACO will update and complete component specifications.” However, we are unable to evaluate the adequacy of your corrective action because you did not provide updated finished product specifications for review. Additionally, Appendix 2, which you appear to suggest included a copy of revised specifications, was not included in your response.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish component specifications that are necessary to ensure specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, you have not established ingredient specifications to ensure the purity, strength, and composition of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> (120 Capsules, Batch: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (60 capsules, Batch: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufactured on&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>). When establishing such specifications, a list of tests, or references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges, or other criteria for the tests described should be included.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your response received December 30, 2021, which states, “MCACO initiated an initial review of specifications of components. . .. By March 31, 2022, MCACO will complete the update of component specifications. By April 30, 2022, MCACO will ensure that all involved personnel are trained and updated on the new specification requirements for purchasing, receiving, and testing of components.” However, we are unable to evaluate the adequacy of your corrective action because you did not provide updated component specifications for our review.\u003C\u002Fp>\n\n\u003Cp>3. You failed to qualify a supplier of a component by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations, as required by 21 CFR 111.75(a)(2)(ii)(A). Specifically, you received from your suppliers Turmeric Root Powder (Supplier Lot: \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and Milk Thistle Seed Extract (Supplier Lot:&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for use in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Amla Powder (Supplier Lot:&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and Beet Root Powder (Supplier Lot: \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for use in your&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and relied on their Certificate of Analysis (COA) for microbiological testing and heavy metals without first establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations. Additionally, you have never conducted heavy metal and microbiological tests to confirm results provided by the supplier’s COA.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your response received on December 30, 2021, which states that you reviewed your procedure for Supplier Partnership Program \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that you will update specific elements to document and establish the reliability of suppliers by March 31, 2022. You stated that by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, MCACO will set up a random testing method for verification of supplier components, which could be internal or external compared to the reported certificate of analysis of each supplier. You also stated that by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, MCACO will have completed all reliability of suppliers through additional testing as necessary to confirm and verify the results of supplier certificates. Your response also provided a document titled, “Supplier Partnership Program” as Appendix 2, Attachment 2. We are unable to evaluate the adequacy of your corrective actions because you did not provide documentation to support that you have qualified the results of your supplier’s certificate of analysis for you to be able to rely on their microbial and heavy metal results.\u003C\u002Fp>\n\n\u003Cp>4. You failed to verify that the laboratory examination and testing methodologies are appropriate for their intended use, as required by 21 CFR 111.320(a). Specifically, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary supplement contains \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You conduct infrared testing (IR) on the finished product, purportedly to confirm the identity and composition of the contents; however, the results of your IR tests do not identify the identity and composition of the contents encapsulated as the finished dietary supplement.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your response received December 30, 2021, which acknowledges that you do not have documentation of the testing methods used in certain documents, specifically for microbial testing and heavy metal testing. Your response states the tests performed were not documented on the specification’s sheets for components or finished product and that there was no documentation for the reasoning of using IR testing for identification of final product. You state that, on December 23, 2021, you reviewed and identified the policies, procedures and forms that were missing the testing method used for results, and that by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to have updated all the related documents (e.g., supplier partnership program, specifications of components, specifications of final product, Master Manufacturing Record, Batch production records and final product Certificates of Analysis) and that you will document the reason for using IR testing for identification. We are unable to evaluate the adequacy of your corrective actions because you did not provide documentation to verify that the laboratory examination and testing methodologies that you use are appropriate for their intended use.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish master manufacturing records (MMRs) that include all required components of 21 CFR 111.210. Specifically, your master manufacturing records for&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (120 Capsules) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (60 Capsules) failed to include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredient list of the dietary supplement [21 CFR 111.210(d)];\u003C\u002Fli>\n\t\u003Cli>A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)]; and\u003C\u002Fli>\n\t\u003Cli>Written instructions, including specific actions necessary to perform and verify points, steps or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(3)].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We acknowledge your response, received on December 30, 2021, in which you state you have reviewed a sampling of MMRs and determined that certain elements are missing including verification points. You also state that since production of various products is limited to&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, you will ensure that elements in their MMRs are updated by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We are unable to evaluate the adequacy of your corrective actions because you did not provide an updated MMR for review.\u003C\u002Fp>\n\n\u003Cp>6. You failed to establish and follow laboratory control processes that are reviewed and approved by quality control personnel, including the use of criteria for selecting standard reference materials used in performing test and examinations, as required by 21 CFR 111.315(d). Specifically, your Product Testing and Release Procedure (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) states each time a component is analyzed it is added to the IR library as a reference standard. In accordance with your procedure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the IR library as a reference standard; however, your batch analysis does not include data to support that the batch was thoroughly characterized to ensure its identity, purity, quality, and strength. When using in-house or non-compendia reference standards, the batch should be prepared from a representative lot that is thoroughly characterized to be acceptable as a reference standard using appropriate testing methodologies.\u003C\u002Fp>\n\n\u003Cp>7. You failed to ensure that the person who conducts a material review and makes the disposition decision, at the time of performance, documented that material review and disposition decision, as required by 21 CFR 111.113(c). Specifically, on November 4, 2021, your management provided our investigator a copy of the BPR for an unreleased batch of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (60 capsules, Batch: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufactured on&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>). On November 17, 2021, your management provided our Investigator a copy of the documentation relating to the same batch, except that the November 17, 2021, version of the BPR provided to our investigator had been completed and approved for release, signed, and dated September 29, 2021 (over a month before an unsigned and undated version of this document was first provided to our investigator). The documentation for this batch demonstrates that the documentation of the material review and disposition decision was not made at the time of performance. Additionally, note that 21 CFR 111.260(m) requires documentation at the time of performance any required material review and disposition decision. The expectation is that you will accurately document the current date at the time of the review and disposition.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov (preferred) or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at 214-253-5205 or by email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia, Jr.\u003Cbr>\nProgram Division Director HAF West 3\u003Cbr>\nDallas District Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Erik Aguayo\n\nRecipient Title\n\nCOO\n\nMCACO, LTD\n\n1610 W. Polo Rd\n\nGrand Prairie, TX 75052\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West III\n\nUnited States\n\nWARNING LETTER\n\nApril 21, 2022\n\nRef: CMS # 624606\n\nDear Mr. Aguayo,\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 1610 W. Polo Rd, Grand Prairie, TX from November 4, 2021, through December 7, 2021. Based on the inspectional findings we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nAdulterated Dietary Supplements\n\nThe inspection of your facility revealed serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations, Part 111 (21 CFR 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. FDA acknowledges the receipt of your e-mail correspondence dated December 30, 2021, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\n\nThe significant violations documented during the inspection include, but are not limited to, the following:\n\n1. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, your finished product specifications for (b)(4) and (b)(4) fail to include established specifications for purity, strength, and composition for the dietary supplement products. When establishing such specifications, a list of tests or references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges, or other criteria for the tests described should be included.\n\nWe acknowledge your response, received December 30, 2021, which acknowledged that specific elements needed to be updated and asserted that “[b]y March 31, 2022, MCACO will update and complete component specifications.” However, we are unable to evaluate the adequacy of your corrective action because you did not provide updated finished product specifications for review. Additionally, Appendix 2, which you appear to suggest included a copy of revised specifications, was not included in your response.\n\n2. You failed to establish component specifications that are necessary to ensure specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, you have not established ingredient specifications to ensure the purity, strength, and composition of your (b)(4) (120 Capsules, Batch: (b)(4), manufactured on (b)(4)) and (b)(4) (60 capsules, Batch: (b)(4), manufactured on (b)(4)). When establishing such specifications, a list of tests, or references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges, or other criteria for the tests described should be included.\n\nWe acknowledge your response received December 30, 2021, which states, “MCACO initiated an initial review of specifications of components. . .. By March 31, 2022, MCACO will complete the update of component specifications. By April 30, 2022, MCACO will ensure that all involved personnel are trained and updated on the new specification requirements for purchasing, receiving, and testing of components.” However, we are unable to evaluate the adequacy of your corrective action because you did not provide updated component specifications for our review.\n\n3. You failed to qualify a supplier of a component by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations, as required by 21 CFR 111.75(a)(2)(ii)(A). Specifically, you received from your suppliers Turmeric Root Powder (Supplier Lot: (b)(4)) and Milk Thistle Seed Extract (Supplier Lot: (b)(4)) for use in your (b)(4), and Amla Powder (Supplier Lot: (b)(4)) and Beet Root Powder (Supplier Lot: (b)(4)) for use in your (b)(4), and relied on their Certificate of Analysis (COA) for microbiological testing and heavy metals without first establishing the reliability of the supplier's certificate of analysis through confirmation of the results of their tests or examinations. Additionally, you have never conducted heavy metal and microbiological tests to confirm results provided by the supplier’s COA.\n\nWe acknowledge your response received on December 30, 2021, which states that you reviewed your procedure for Supplier Partnership Program (b)(4) and that you will update specific elements to document and establish the reliability of suppliers by March 31, 2022. You stated that by (b)(4), MCACO will set up a random testing method for verification of supplier components, which could be internal or external compared to the reported certificate of analysis of each supplier. You also stated that by (b)(4), MCACO will have completed all reliability of suppliers through additional testing as necessary to confirm and verify the results of supplier certificates. Your response also provided a document titled, “Supplier Partnership Program” as Appendix 2, Attachment 2. We are unable to evaluate the adequacy of your corrective actions because you did not provide documentation to support that you have qualified the results of your supplier’s certificate of analysis for you to be able to rely on their microbial and heavy metal results.\n\n4. You failed to verify that the laboratory examination and testing methodologies are appropriate for their intended use, as required by 21 CFR 111.320(a). Specifically, your (b)(4) dietary supplement contains (b)(4), and (b)(4). You conduct infrared testing (IR) on the finished product, purportedly to confirm the identity and composition of the contents; however, the results of your IR tests do not identify the identity and composition of the contents encapsulated as the finished dietary supplement.\n\nWe acknowledge your response received December 30, 2021, which acknowledges that you do not have documentation of the testing methods used in certain documents, specifically for microbial testing and heavy metal testing. Your response states the tests performed were not documented on the specification’s sheets for components or finished product and that there was no documentation for the reasoning of using IR testing for identification of final product. You state that, on December 23, 2021, you reviewed and identified the policies, procedures and forms that were missing the testing method used for results, and that by (b)(4), you plan to have updated all the related documents (e.g., supplier partnership program, specifications of components, specifications of final product, Master Manufacturing Record, Batch production records and final product Certificates of Analysis) and that you will document the reason for using IR testing for identification. We are unable to evaluate the adequacy of your corrective actions because you did not provide documentation to verify that the laboratory examination and testing methodologies that you use are appropriate for their intended use.\n\n5. You failed to establish master manufacturing records (MMRs) that include all required components of 21 CFR 111.210. Specifically, your master manufacturing records for (b)(4) (120 Capsules) and (b)(4) (60 Capsules) failed to include:\n\nThe identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredient list of the dietary supplement [21 CFR 111.210(d)];\n\nA description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)]; and\n\nWritten instructions, including specific actions necessary to perform and verify points, steps or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(3)].\n\nWe acknowledge your response, received on December 30, 2021, in which you state you have reviewed a sampling of MMRs and determined that certain elements are missing including verification points. You also state that since production of various products is limited to (b)(4), you will ensure that elements in their MMRs are updated by (b)(4). We are unable to evaluate the adequacy of your corrective actions because you did not provide an updated MMR for review.\n\n6. You failed to establish and follow laboratory control processes that are reviewed and approved by quality control personnel, including the use of criteria for selecting standard reference materials used in performing test and examinations, as required by 21 CFR 111.315(d). Specifically, your Product Testing and Release Procedure ((b)(4)) states each time a component is analyzed it is added to the IR library as a reference standard. In accordance with your procedure, (b)(4) Batch (b)(4) was added to the IR library as a reference standard; however, your batch analysis does not include data to support that the batch was thoroughly characterized to ensure its identity, purity, quality, and strength. When using in-house or non-compendia reference standards, the batch should be prepared from a representative lot that is thoroughly characterized to be acceptable as a reference standard using appropriate testing methodologies.\n\n7. You failed to ensure that the person who conducts a material review and makes the disposition decision, at the time of performance, documented that material review and disposition decision, as required by 21 CFR 111.113(c). Specifically, on November 4, 2021, your management provided our investigator a copy of the BPR for an unreleased batch of (b)(4) (60 capsules, Batch: (b)(4), manufactured on (b)(4)). On November 17, 2021, your management provided our Investigator a copy of the documentation relating to the same batch, except that the November 17, 2021, version of the BPR provided to our investigator had been completed and approved for release, signed, and dated September 29, 2021 (over a month before an unsigned and undated version of this document was first provided to our investigator). The documentation for this batch demonstrates that the documentation of the material review and disposition decision was not made at the time of performance. Additionally, note that 21 CFR 111.260(m) requires documentation at the time of performance any required material review and disposition decision. The expectation is that you will accurately document the current date at the time of the review and disposition.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov (preferred) or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at 214-253-5205 or by email.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia, Jr.\n\nProgram Division Director HAF West 3\n\nDallas District Director","MCACO, LTD","mcaco-ltd-624606-04212022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcaco-ltd-624606-04212022","2026-10-26T08:09:22.038035+00:00","Warning Letter","Issued","2022-05-10","624606","Dietary SupplementsDrugs","Mr. Erik Aguayo","2026-08-20T01:55:14.424+00:00","Via Overnight Delivery","2022-04-21",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":24,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":20,"body_fetched_at":50,"delivery_method":51,"recipient_title":20,"reference_number":52,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},1038,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-03-07T05:00:00Z\">03\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-06T05:00:00Z\">03\u002F06\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcvapour-llc-697988-03062025\">McVapour LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2401101\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>McVapour LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1712 North Nelson Drive, Unit B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Derby\u003C\u002Fspan>, \u003Cspan>KS\u003C\u002Fspan> \u003Cspan>67037\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 6, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that McVapour LLC manufactures, sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. §1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. §321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquidproducts, containing nicotine from any source, must be in compliance with the FD&amp;C Act and itsimplementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. §387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2)the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Caribou Lou.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2401101, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2401101\n\nProduct:\n\nTobacco\n\nRecipient:\n\nMcVapour LLC\n\n1712 North Nelson Drive, Unit B\n\nDerby, KS 67037\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 6, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that McVapour LLC manufactures, sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. §1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. §321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquidproducts, containing nicotine from any source, must be in compliance with the FD&C Act and itsimplementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. §387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2)the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Caribou Lou.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2401101, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","McVapour LLC","mcvapour-llc-697988-03062025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcvapour-llc-697988-03062025","2026-10-26T08:09:22.284474+00:00","2025-03-07","697988","Tobacco","2026-08-19T16:59:31.779+00:00","VIA UPS and Electronic Mail","ER2401101","2025-03-06",{"id":55,"raw":56,"subject":61,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":20,"letter_url":68,"updated_at":69,"action_type":23,"case_status":70,"posted_date":71,"marcs_cms_no":72,"product_type":73,"closeout_date":74,"issuing_office":75,"recipient_name":76,"body_fetched_at":77,"delivery_method":78,"recipient_title":20,"reference_number":20,"action_taken_date":79,"medical_device_id":20,"response_letter_date":20},1561,[57,58,59,60,61,13,62,13],"\u003Ctime datetime=\"2024-03-19T13:20:00Z\">03\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-12T04:00:00Z\">03\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffurst-mcness-company-668925-03122024\">Furst-McNess Company\u003C\u002Fa>"," Division of Human and Animal Food Operations West I","CGMP\u002FMedicated Feeds\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffurst-mcness-company-668925-04302026\">\u003Ctime datetime=\"2026-05-04T04:00:00Z\">05\u002F04\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark Poeschl\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Furst-McNess Company\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1252 Bell Valley Road, Suite 220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rockford\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>61108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 12, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Refer to CMS 668925\u003Cbr>\n\u003Cbr>\nDear Mr. Poeschl:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your non-FDA licensed medicated animal food manufacturing facility (feed mill), located at W9077 Schutz Road, Lodi, Wisconsin, from August 23 through 28, 2023. This inspection was initiated in response to a Reportable Food Registry (RFR) report involving multiple goat illnesses and deaths after the goats consumed medicated goat feed that contained monensin (Product B9251, 18% Goat Starter, lot number 071423) that was manufactured at your facility. On August 21, 2023, you initiated a voluntary Class I recall of this goat feed due to excessive monensin.\u003C\u002Fp>\n\n\u003Cp>During the inspection the FDA investigator found evidence that you manufactured and distributed a goat feed, Product B9251, 18% Goat Starter, lot number 071423, that contained a super-potent concentration of the new animal drug monensin. This Type C medicated goat feed containing the Type A medicated article monensin is unsafe because the new animal drug was not used in conformance with the drug approval.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> As a result, the goat feed containing the new animal drug is adulterated.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition, the inspection revealed a significant violation of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements in Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu>, Part 507 (21 CFR Part 507), which causes your products to be adulterated.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR Part 507 is a prohibited act.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Furthermore, FDA’s investigator found evidence of a significant violation of the Current Good Manufacturing Practice (CGMP) for Medicated Feeds requirements, 21 CFR Part 225. Failure of your medicated feed mill to comply with these requirements causes your medicated feed to be adulterated.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>The doing of any act to a food or drug after shipment of the food or drug and\u002For its components in interstate commerce and while the food or drug is held for sale (whether or not the first sale) that results in the food or drug being adulterated or misbranded is prohibited.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>You may find the FD&amp;C Act and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection you were issued a Form FDA-483, Inspectional Observations (FDA-483). We received your written responses dated September 1 and 12, 2023, and address your corrective actions below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility the FDA investigator observed evidence of a significant violation of these requirements:\u003C\u002Fp>\n\n\u003Cp>1. You did not identify and implement a preventive control to provide assurance that any hazard requiring a preventive control will be significantly minimized or prevented, as required by 21 CFR 507.34(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, your hazard analysis determined that monensin requires a preventive control to avoid the known hazard of “high medication in feed.” Your food safety plan identified a preventive control to be applied at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step. You identified this preventive control as “Process Control-\u003Cstrong>(b)(4)\u003C\u002Fstrong> Monensin 90 PC 001 Drug Receipt &amp; Inventory \u003Cstrong>(b)(4)\u003C\u002Fstrong> Report of Monensin or Mill mix for minerals.” This preventive control requires a \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug inventory reconciliation and a second reviewer signature on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> report. Your preventive control has a “parameter” of a second sign-off being recorded on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Monensin 90 PC 001 Drug Receipt &amp; Inventory and \u003Cstrong>(b)(4)\u003C\u002Fstrong> reports. Your second sign-off is not a parameter.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>This preventive control is inadequate. For example, on July 14, 2023, your employee added \u003Cstrong>(b)(4)\u003C\u002Fstrong> of monensin to lot 071423 of your Product B9251, 18% Goat Starter. However, this formulation of your 18% Goat Starter required only \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds of monensin and this error resulted in a super-potent monensin concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the finished goat feed. This super-potent concentration was over \u003Cstrong>(b)(4)\u003C\u002Fstrong> times above the labeled monensin concentration of 20g\u002Fton in the finished goat feed. You shipped the super-potent finished goat feed to four customers, who reported goat illnesses and deaths after their goats consumed the feed.\u003C\u002Fp>\n\n\u003Cp>During your investigation into the cause of this error you determined your employee “grabbed the wrong raw material.” However, the Mill Mix Report called for Monovet 90 and your documents indicate your employees used Monovet 90.\u003C\u002Fp>\n\n\u003Cp>Your investigation also determined that the “second signature [process] was not followed properly.” However, your documents show two employees initialed both the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Monensin 90 PC 001 Drug Receipt &amp; Inventory and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Report. Your&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Monensin 90 PC 001 Drug Receipt &amp; Inventory tracks the medicated article removed and physically weighed out for each medicated production run. This is then compared to your actual drug inventory and recorded as the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug inventory. However, your preventive control does not ensure that the amount of drug pulled from inventory and the amount of drug added to the production batch are compared to the product’s intended formulation as noted on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Report.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your written responses to the FDA-483 and information you provided to the FDA investigator during the inspection that describe corrective actions you have taken or plan to take to address this observation, including employee retraining, revising your food safety plan by adding a comparison of your inventory with your electronic \u003Cstrong>(b)(4)\u003C\u002Fstrong> usage report, and conducting a \u003Cstrong>(b)(4)\u003C\u002Fstrong> physical inventory of drugs. Your responses did not include documentation of these corrective actions. Therefore, we are unable to fully evaluate them. More importantly, your corrections provided at the close of the inspection and in response to the FDA-483 continue to identify the second sign-off as your preventive control which, as stated above, is a demonstrably inadequate preventive control to ensure the amount of drug weighed and added to the batch matches the amount identified in the formulation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice for Medicated Feeds Requirements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your facility is required to follow the medicated feed CGMP regulations for non-licensed, medicated animal feed manufacturers found in 21 CFR 225.120–202. During the inspection of your facility the FDA investigator observed evidence of a significant violation of these requirements:\u003C\u002Fp>\n\n\u003Cp>2. You did not establish and maintain adequate procedures for the identification, storage, and inventory control (receipt and use) of all Type A medicated articles and Type B medicated feeds intended for use in the manufacture of medicated feeds to aid in assuring the identity, strength, quality, and purity of these drug sources. All Type A medicated articles and Type B medicated feeds must be used in accordance with their labeled mixing directions, as required by 21 CFR 225.142.\u003C\u002Fp>\n\n\u003Cp>Specifically, while the formula for your Product B9251, 18% Goat Starter, called for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of monensin Type A medicated article (consistent with the labeled mixing directions), your records show that on July 14, 2023, your employee added \u003Cstrong>(b)(4)\u003C\u002Fstrong> of a monensin Type A medicated article to lot 071423 of your Product B9251, 18% Goat Starter.\u003C\u002Fp>\n\n\u003Cp>A review of your F 789 Monensin 90 PC 001 Drug Receipt &amp; Inventory Record Lot No VSB213 and your Production Run Summary Report 159067 for Formula (Product) B9251 produced on July 14, 2023, revealed that the records were not in agreement. Your F 789 Monensin 90 PC 001 Drug Receipt &amp; Inventory Record Lot No VSB213 for the date of July 13, 2023, documents \u003Cstrong>(b)(4)\u003C\u002Fstrong> were pulled from inventory for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch of Product B9251. Your Production Run Summary Report 159067 for Formula (Product) B9251 produced on July 14, 2023, documents that only \u003Cstrong>(b)(4)\u003C\u002Fstrong> were placed into the batch.\u003C\u002Fp>\n\n\u003Cp>In addition, your F 789 Monensin 90 PC 001 Drug Receipt &amp; Inventory Record Lot No VSB213 and your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Report for Formula (Product) B9251 indicate the drug inventorying and the drug inclusion into production run 159067 were performed by the same individuals, neither of whom noted the amount pulled from the drug inventory exceeded the quantity required on the Hand ADD WEM Report. Your procedures indicate that an “Inventory Control Supervisor or SAP Support” will verify \u003Cstrong>(b)(4)\u003C\u002Fstrong> that there are two signatures on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Report. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> Report for Formula (Product) B9251 dated July 13, 2023, was not signed and dated as being reviewed by an “Inventory Control Supervisor or SAP Support.” Furthermore, there was no documentation the records were verified by anyone for accuracy (theoretical usage based on formula versus actual medicated article pulled from inventory for production) prior to or following the distribution of Product B9251, 18% Goat Starter, lot 071423.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your verbal responses at the close of the inspection and your written responses to the FDA-483 that describe corrective actions you have taken or plan to take to address this observation, including employee retraining, conducting a \u003Cstrong>(b)(4)\u003C\u002Fstrong> physical inventory of drugs, and comparison of your inventory with your electronic \u003Cstrong>(b)(4)\u003C\u002Fstrong> usage report. However, a comparison of your daily inventory and the theoretical inventory along with a review and comparison with your production and your electronic \u003Cstrong>(b)(4)\u003C\u002Fstrong> usage report would not be adequate without a comparison to the formulas produced. Further, your response does not include supporting documentation to demonstrate your corrections have been completed and are consistently implemented. Therefore, we are unable to fully evaluate the adequacy of your response. We encourage you to provide documentation of your corrective actions in follow-up correspondence.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also have the following comments:\u003C\u002Fp>\n\n\u003Cp>• Any preventive control that you establish is subject to preventive control management components, as required by 21 CFR 507.39. These management components include:\u003Cbr>\n&nbsp; &nbsp; o Monitoring in accordance with 21 CFR 507.40, which requires that you establish and implement written procedures for monitoring preventive controls, monitor the preventive controls with adequate frequency to provide assurance that they are consistently performed, and document the monitoring of preventive controls in records that are subject to verification that monitoring is being conducted,\u003Csup>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and records review.\u003Csup>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003Cbr>\n&nbsp; &nbsp; o Corrective actions and corrections in accordance with 21 CFR 507.42, which require that you establish and implement written corrective action procedures that must be taken if preventive controls are not properly implemented; and\u003Cbr>\n&nbsp; &nbsp; o Verification in accordance with 21 CFR 507.45, which must include, as appropriate, verification that monitoring is being conducted, verification that appropriate decisions about corrective actions are being made, verification of implementation and effectiveness, and re-analysis of your food safety plan. Verification activities must be documented in records.\u003Cbr>\n• For more information about FDA’s current thinking on the requirements of 21 CFR\u003Cbr>\nPart 507, see:\u003C\u002Fp>\n\n\u003Cp>Guidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals,” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload;\u003C\u002Fp>\n\n\u003Cp>Guidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals,” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload;\u003C\u002Fp>\n\n\u003Cp>Draft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program,” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Within 15 working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your written response to Carolyn A. Warren, Compliance Officer, U.S. Food and Drug Administration, at 250 Marquette Ave, Suite 600, Minneapolis, MN 55401, or email to Carolyn.Warren@fda.hhs.gov. If you have questions regarding any issues in this letter, you may contact Compliance Officer Warren at (612) 758-7182.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Greg Smith, PharmD\u003Cbr>\nActing Program Division Director, West Division 1\u003Cbr>\nOffice of Human and Animal Food Operations\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Section 512(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), [21 U.S.C. § 360b(a)(2)(A)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See Section 501(a)(6) of the FD&amp;C Act [21 U.S.C. § 351(a)(6)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(4) of the FD&amp;C Act [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(uu) of the FD&amp;C Act [21 U.S.C. § 331(uu)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See Section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR 225.1(b)(1).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> For a discussion of parameters in the context of process controls, see GFI #245, Hazard Analysis and Risk-Based Preventive Controls for Food for Animals, pp. 67-68, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 507.45(a)(2).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 507.49(a) which says in part, “You must verify that the preventive controls are consistently implemented and are effectively and significantly minimizing hazards. To do so, you must conduct activities that include the following . . . Review … by (or under the oversight of) a preventive controls qualified individual . . . [of m]onitoring and corrective action records within 7 working days after the records are created or within a reasonable timeframe . . ..”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nAnimal & Veterinary\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMark Poeschl\n\nRecipient Title\n\nChief Executive Officer\n\nFurst-McNess Company\n\n1252 Bell Valley Road, Suite 220\n\nRockford, IL 61108\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West I\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nMarch 12, 2024\n\nWARNING LETTER\n\nRefer to CMS 668925\n\nDear Mr. Poeschl:\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your non-FDA licensed medicated animal food manufacturing facility (feed mill), located at W9077 Schutz Road, Lodi, Wisconsin, from August 23 through 28, 2023. This inspection was initiated in response to a Reportable Food Registry (RFR) report involving multiple goat illnesses and deaths after the goats consumed medicated goat feed that contained monensin (Product B9251, 18% Goat Starter, lot number 071423) that was manufactured at your facility. On August 21, 2023, you initiated a voluntary Class I recall of this goat feed due to excessive monensin.\n\nDuring the inspection the FDA investigator found evidence that you manufactured and distributed a goat feed, Product B9251, 18% Goat Starter, lot number 071423, that contained a super-potent concentration of the new animal drug monensin. This Type C medicated goat feed containing the Type A medicated article monensin is unsafe because the new animal drug was not used in conformance with the drug approval.1 As a result, the goat feed containing the new animal drug is adulterated.2\n\nIn addition, the inspection revealed a significant violation of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which causes your products to be adulterated.3 Failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR Part 507 is a prohibited act.4\n\nFurthermore, FDA’s investigator found evidence of a significant violation of the Current Good Manufacturing Practice (CGMP) for Medicated Feeds requirements, 21 CFR Part 225. Failure of your medicated feed mill to comply with these requirements causes your medicated feed to be adulterated.5\n\nThe doing of any act to a food or drug after shipment of the food or drug and\u002For its components in interstate commerce and while the food or drug is held for sale (whether or not the first sale) that results in the food or drug being adulterated or misbranded is prohibited.6\n\nYou may find the FD&C Act and FDA’s regulations through links on FDA’s website at www.fda.gov.\n\nAt the close of the inspection you were issued a Form FDA-483, Inspectional Observations (FDA-483). We received your written responses dated September 1 and 12, 2023, and address your corrective actions below.\n\nHazard Analysis and Risk-Based Preventive Controls Requirements\n\nYour animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility the FDA investigator observed evidence of a significant violation of these requirements:\n\n1. You did not identify and implement a preventive control to provide assurance that any hazard requiring a preventive control will be significantly minimized or prevented, as required by 21 CFR 507.34(a)(1).\n\nSpecifically, your hazard analysis determined that monensin requires a preventive control to avoid the known hazard of “high medication in feed.” Your food safety plan identified a preventive control to be applied at the “(b)(4)” step. You identified this preventive control as “Process Control-(b)(4) Monensin 90 PC 001 Drug Receipt & Inventory (b)(4) Report of Monensin or Mill mix for minerals.” This preventive control requires a (b)(4) drug inventory reconciliation and a second reviewer signature on the (b)(4) report. Your preventive control has a “parameter” of a second sign-off being recorded on the (b)(4) Monensin 90 PC 001 Drug Receipt & Inventory and (b)(4) reports. Your second sign-off is not a parameter.7\n\nThis preventive control is inadequate. For example, on July 14, 2023, your employee added (b)(4) of monensin to lot 071423 of your Product B9251, 18% Goat Starter. However, this formulation of your 18% Goat Starter required only (b)(4) pounds of monensin and this error resulted in a super-potent monensin concentration of (b)(4) in the finished goat feed. This super-potent concentration was over (b)(4) times above the labeled monensin concentration of 20g\u002Fton in the finished goat feed. You shipped the super-potent finished goat feed to four customers, who reported goat illnesses and deaths after their goats consumed the feed.\n\nDuring your investigation into the cause of this error you determined your employee “grabbed the wrong raw material.” However, the Mill Mix Report called for Monovet 90 and your documents indicate your employees used Monovet 90.\n\nYour investigation also determined that the “second signature [process] was not followed properly.” However, your documents show two employees initialed both the (b)(4) Monensin 90 PC 001 Drug Receipt & Inventory and the (b)(4) Report. Your (b)(4) Monensin 90 PC 001 Drug Receipt & Inventory tracks the medicated article removed and physically weighed out for each medicated production run. This is then compared to your actual drug inventory and recorded as the (b)(4) drug inventory. However, your preventive control does not ensure that the amount of drug pulled from inventory and the amount of drug added to the production batch are compared to the product’s intended formulation as noted on the (b)(4) Report.\n\nWe acknowledge your written responses to the FDA-483 and information you provided to the FDA investigator during the inspection that describe corrective actions you have taken or plan to take to address this observation, including employee retraining, revising your food safety plan by adding a comparison of your inventory with your electronic (b)(4) usage report, and conducting a (b)(4) physical inventory of drugs. Your responses did not include documentation of these corrective actions. Therefore, we are unable to fully evaluate them. More importantly, your corrections provided at the close of the inspection and in response to the FDA-483 continue to identify the second sign-off as your preventive control which, as stated above, is a demonstrably inadequate preventive control to ensure the amount of drug weighed and added to the batch matches the amount identified in the formulation.\n\nCurrent Good Manufacturing Practice for Medicated Feeds Requirements\n\nYour facility is required to follow the medicated feed CGMP regulations for non-licensed, medicated animal feed manufacturers found in 21 CFR 225.120–202. During the inspection of your facility the FDA investigator observed evidence of a significant violation of these requirements:\n\n2. You did not establish and maintain adequate procedures for the identification, storage, and inventory control (receipt and use) of all Type A medicated articles and Type B medicated feeds intended for use in the manufacture of medicated feeds to aid in assuring the identity, strength, quality, and purity of these drug sources. All Type A medicated articles and Type B medicated feeds must be used in accordance with their labeled mixing directions, as required by 21 CFR 225.142.\n\nSpecifically, while the formula for your Product B9251, 18% Goat Starter, called for (b)(4) of monensin Type A medicated article (consistent with the labeled mixing directions), your records show that on July 14, 2023, your employee added (b)(4) of a monensin Type A medicated article to lot 071423 of your Product B9251, 18% Goat Starter.\n\nA review of your F 789 Monensin 90 PC 001 Drug Receipt & Inventory Record Lot No VSB213 and your Production Run Summary Report 159067 for Formula (Product) B9251 produced on July 14, 2023, revealed that the records were not in agreement. Your F 789 Monensin 90 PC 001 Drug Receipt & Inventory Record Lot No VSB213 for the date of July 13, 2023, documents (b)(4) were pulled from inventory for a (b)(4) batch of Product B9251. Your Production Run Summary Report 159067 for Formula (Product) B9251 produced on July 14, 2023, documents that only (b)(4) were placed into the batch.\n\nIn addition, your F 789 Monensin 90 PC 001 Drug Receipt & Inventory Record Lot No VSB213 and your (b)(4) Report for Formula (Product) B9251 indicate the drug inventorying and the drug inclusion into production run 159067 were performed by the same individuals, neither of whom noted the amount pulled from the drug inventory exceeded the quantity required on the Hand ADD WEM Report. Your procedures indicate that an “Inventory Control Supervisor or SAP Support” will verify (b)(4) that there are two signatures on the (b)(4) Report. The (b)(4) Report for Formula (Product) B9251 dated July 13, 2023, was not signed and dated as being reviewed by an “Inventory Control Supervisor or SAP Support.” Furthermore, there was no documentation the records were verified by anyone for accuracy (theoretical usage based on formula versus actual medicated article pulled from inventory for production) prior to or following the distribution of Product B9251, 18% Goat Starter, lot 071423.\n\nWe acknowledge your verbal responses at the close of the inspection and your written responses to the FDA-483 that describe corrective actions you have taken or plan to take to address this observation, including employee retraining, conducting a (b)(4) physical inventory of drugs, and comparison of your inventory with your electronic (b)(4) usage report. However, a comparison of your daily inventory and the theoretical inventory along with a review and comparison with your production and your electronic (b)(4) usage report would not be adequate without a comparison to the formulas produced. Further, your response does not include supporting documentation to demonstrate your corrections have been completed and are consistently implemented. Therefore, we are unable to fully evaluate the adequacy of your response. We encourage you to provide documentation of your corrective actions in follow-up correspondence.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to legal action including, without limitation, seizure and injunction.\n\nWe also have the following comments:\n\n• Any preventive control that you establish is subject to preventive control management components, as required by 21 CFR 507.39. These management components include:\n\no Monitoring in accordance with 21 CFR 507.40, which requires that you establish and implement written procedures for monitoring preventive controls, monitor the preventive controls with adequate frequency to provide assurance that they are consistently performed, and document the monitoring of preventive controls in records that are subject to verification that monitoring is being conducted,8 and records review.9\n\no Corrective actions and corrections in accordance with 21 CFR 507.42, which require that you establish and implement written corrective action procedures that must be taken if preventive controls are not properly implemented; and\n\no Verification in accordance with 21 CFR 507.45, which must include, as appropriate, verification that monitoring is being conducted, verification that appropriate decisions about corrective actions are being made, verification of implementation and effectiveness, and re-analysis of your food safety plan. Verification activities must be documented in records.\n\n• For more information about FDA’s current thinking on the requirements of 21 CFR\n\nPart 507, see:\n\nGuidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals,” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload;\n\nGuidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals,” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload;\n\nDraft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program,” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload.\n\nWithin 15 working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your written response to Carolyn A. Warren, Compliance Officer, U.S. Food and Drug Administration, at 250 Marquette Ave, Suite 600, Minneapolis, MN 55401, or email to Carolyn.Warren@fda.hhs.gov. If you have questions regarding any issues in this letter, you may contact Compliance Officer Warren at (612) 758-7182.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Greg Smith, PharmD\n\nActing Program Division Director, West Division 1\n\nOffice of Human and Animal Food Operations\n\n_____________________\n\n1 See Section 512(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), [21 U.S.C. § 360b(a)(2)(A)].\n\n2 See Section 501(a)(6) of the FD&C Act [21 U.S.C. § 351(a)(6)].\n\n3 See Section 402(a)(4) of the FD&C Act [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\n\n4 See Section 301(uu) of the FD&C Act [21 U.S.C. § 331(uu)].\n\n5 See Section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR 225.1(b)(1).\n\n6 See Section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].\n\n7 For a discussion of parameters in the context of process controls, see GFI #245, Hazard Analysis and Risk-Based Preventive Controls for Food for Animals, pp. 67-68, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload.\n\n8 See 21 CFR 507.45(a)(2).\n\n9 See 21 CFR 507.49(a) which says in part, “You must verify that the preventive controls are consistently implemented and are effectively and significantly minimizing hazards. To do so, you must conduct activities that include the following . . . Review … by (or under the oversight of) a preventive controls qualified individual . . . [of m]onitoring and corrective action records within 7 working days after the records are created or within a reasonable timeframe . . ..”","Furst-McNess Company","furst-mcness-company-668925-03122024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffurst-mcness-company-668925-03122024","2026-10-26T08:08:44.202716+00:00","Closed Out","2024-03-19","668925","Animal & VeterinaryFood & Beverages","2026-05-04","Division of Human and Animal Food Operations West I","Mark Poeschl","2026-08-20T00:13:52.453+00:00","VIA UPS","2024-03-12",{"id":81,"raw":82,"subject":87,"body_html":88,"body_text":89,"firm_name":90,"letter_id":91,"created_at":92,"fei_number":20,"letter_url":93,"updated_at":94,"action_type":23,"case_status":24,"posted_date":95,"marcs_cms_no":96,"product_type":97,"closeout_date":20,"issuing_office":86,"recipient_name":98,"body_fetched_at":99,"delivery_method":78,"recipient_title":20,"reference_number":20,"action_taken_date":100,"medical_device_id":20,"response_letter_date":20},2371,[83,84,85,86,87,13,13,13],"\u003Ctime datetime=\"2022-11-01T13:20:00Z\">11\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-18T04:00:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcconnell-labs-inc-638958-10182022\">McConnell Labs Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jim McConnell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>McConnell Labs Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>406 SW Umatilla Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Redmond\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97756\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 18, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McConnell:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the U. S. Food and Drug Administration as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). The FDA has reviewed the records you submitted in response to our July 30, 2021, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 374(a)(4)) for your facility, McConnell Labs Inc., FEI 3010298400, at 406 SW Umatilla Ave., Redmond, OR.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR) parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYour firm manufactured OTC drug products, including Light Elegance Hand Sanitizer.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Your response to our request for records and other information under section 704(a)(4) indicated that you did not adequately test each lot of incoming raw materials (e.g., active ingredients, ethanol, and isopropyl alcohol) used to manufacture your drug products to determine their identity.\u003C\u002Fp>\n\n\u003Cp>For example, in response to our request, you were unable to provide evidence that you performed any testing on your incoming raw materials. Instead, you only provided your suppliers’ Certificates of Analysis (COA). Additionally, your ethanol supplier’s COA states that the product “is not intended for use as an active ingredient in drug manufacturing nor as a medical device or disinfectant.”\u003C\u002Fp>\n\n\u003Cp>In addition, in your response, you state that you do not test for methanol on any incoming lots of ethanol and isopropyl alcohol. The use of ethanol or isopropyl alcohol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See the FDA’s guidance document, \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem>, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality, including testing for the presence of methanol in ethanol and isopropyl.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not conduct adequate finished drug product testing on all drug products.\u003C\u002Fp>\n\n\u003Cp>Specifically, in response to our request to provide release test specifications, analytical procedures for the analysis of drug products and testing data, you submitted, in part, a procedure stating you evaluate the alcohol concentration of your hand sanitizers. However, you also provided your COA reports and batch records which demonstrated that your hand sanitizer drug products are only tested for weight, density, color, viscosity, and smell.\u003C\u002Fp>\n\n\u003Cp>Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fli>\n\t\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retained samples to determine the quality of all batches of drug product distributed in the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\n\t\u003Cli>A summary of all results including methanol, benzene, acetal, and acetaldehyde for all hand sanitizer batches released and distributed. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate that you established and followed appropriate storage conditions and expiration dates of the drug products manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>Specifically, you reported that the expiry period assigned and applied to your hand sanitizer products is “36 months period [sic] after opening.” You also provided COA reports which state that these products have an expiration “10 years past the manufacturing date.”\u003C\u002Fp>\n\n\u003Cp>You have not provided data to support the multiple expiry periods of your hand sanitizers. Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment, and corrective and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability-indicating methods\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station(timepoint)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should perform a comprehensive audit of your entire operation for CGMP compliance and also evaluate the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please identify your responses with the unique identifier: \u003Cstrong>CMS 638958\u003C\u002Fstrong>. Send your electronic response to ORAPHARM4_Responses@FDA.HHS.GOV with ATTN:CDR Steven E. Porter, Jr., or mail your written response to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact LCDR Rumany Penn, compliance cfficer, at rumany.penn@fda.hhs.gov or (949) 608-4409.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCDR Steven E. Porter, Jr. Director,\u003Cbr>\nDivision of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). Because McConnell Labs Inc.’s hand sanitizer products were not prepared under the circumstances described in this guidance, they do not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Per section 501 of the FD&amp;C Act, “current good manufacturing practice” for the purposes of complying with the requirement in section 501(a)(2)(B) includes “managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jim McConnell\n\nRecipient Title\n\nPresident\n\nMcConnell Labs Inc.\n\n406 SW Umatilla Ave.\n\nRedmond, OR 97756\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nOctober 18, 2022\n\nDear Mr. McConnell:\n\nYour facility is registered with the U. S. Food and Drug Administration as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). The FDA has reviewed the records you submitted in response to our July 30, 2021, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 374(a)(4)) for your facility, McConnell Labs Inc., FEI 3010298400, at 406 SW Umatilla Ave., Redmond, OR.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR) parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYour firm manufactured OTC drug products, including Light Elegance Hand Sanitizer.1. Your response to our request for records and other information under section 704(a)(4) indicated that you did not adequately test each lot of incoming raw materials (e.g., active ingredients, ethanol, and isopropyl alcohol) used to manufacture your drug products to determine their identity.\n\nFor example, in response to our request, you were unable to provide evidence that you performed any testing on your incoming raw materials. Instead, you only provided your suppliers’ Certificates of Analysis (COA). Additionally, your ethanol supplier’s COA states that the product “is not intended for use as an active ingredient in drug manufacturing nor as a medical device or disinfectant.”\n\nIn addition, in your response, you state that you do not test for methanol on any incoming lots of ethanol and isopropyl alcohol. The use of ethanol or isopropyl alcohol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See the FDA’s guidance document, Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19), at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nWithout adequate testing, you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality, including testing for the presence of methanol in ethanol and isopropyl.\n\nIn response to this letter, provide:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.2\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nBased on the records and information you provided, you did not conduct adequate finished drug product testing on all drug products.\n\nSpecifically, in response to our request to provide release test specifications, analytical procedures for the analysis of drug products and testing data, you submitted, in part, a procedure stating you evaluate the alcohol concentration of your hand sanitizers. However, you also provided your COA reports and batch records which demonstrated that your hand sanitizer drug products are only tested for weight, density, color, viscosity, and smell.\n\nFull release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide:\n\nA list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\nAn action plan and timelines for conducting full chemical and microbiological testing of retained samples to determine the quality of all batches of drug product distributed in the United States that are within expiry as of the date of this letter.\n\nA summary of all results including methanol, benzene, acetal, and acetaldehyde for all hand sanitizer batches released and distributed. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nBased on the records and information you provided, you did not demonstrate that you established and followed appropriate storage conditions and expiration dates of the drug products manufactured at your facility.\n\nSpecifically, you reported that the expiry period assigned and applied to your hand sanitizer products is “36 months period [sic] after opening.” You also provided COA reports which state that these products have an expiration “10 years past the manufacturing date.”\n\nYou have not provided data to support the multiple expiry periods of your hand sanitizers. Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment, and corrective and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability-indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station(timepoint)\n\nAll procedures that describe these and other elements of your remediated stability program.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should perform a comprehensive audit of your entire operation for CGMP compliance and also evaluate the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease identify your responses with the unique identifier: CMS 638958. Send your electronic response to ORAPHARM4_Responses@FDA.HHS.GOV with ATTN:CDR Steven E. Porter, Jr., or mail your written response to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nIf you have questions regarding the contents of this letter, please contact LCDR Rumany Penn, compliance cfficer, at rumany.penn@fda.hhs.gov or (949) 608-4409.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr. Director,\n\nDivision of Pharmaceutical Quality Operations IV\n\n__________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because McConnell Labs Inc.’s hand sanitizer products were not prepared under the circumstances described in this guidance, they do not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 Per section 501 of the FD&C Act, “current good manufacturing practice” for the purposes of complying with the requirement in section 501(a)(2)(B) includes “managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.”","McConnell Labs Inc.","mcconnell-labs-inc-638958-10182022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcconnell-labs-inc-638958-10182022","2026-10-26T08:09:22.128953+00:00","2022-11-01","638958","Drugs","Mr. Jim McConnell","2026-08-20T01:28:37.367+00:00","2022-10-18",{"id":102,"raw":103,"subject":109,"body_html":110,"body_text":111,"firm_name":112,"letter_id":113,"created_at":114,"fei_number":20,"letter_url":115,"updated_at":116,"action_type":23,"case_status":24,"posted_date":117,"marcs_cms_no":118,"product_type":97,"closeout_date":20,"issuing_office":107,"recipient_name":119,"body_fetched_at":120,"delivery_method":121,"recipient_title":20,"reference_number":20,"action_taken_date":122,"medical_device_id":20,"response_letter_date":20},3141,[104,105,106,107,108,13,13,13],"\u003Ctime datetime=\"2021-09-14T13:20:00Z\">09\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-07T04:00:00Z\">09\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcdaniel-water-llc-616186-09072021\">McDaniel Water, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gary McDaniel\u002FRuth Shields\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Directors\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>McDaniel Water, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>23711 Hix Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canyon\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>79015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mcdanielwater@gmail.com\"> mcdanielwater@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 7, 2021\u003C\u002Fp>\n\n\u003Cp>Ruth Shields, Director\u003Cbr>\nMcDaniel Water LLC\u003Cbr>\n363 Ricketson Road\u003Cbr>\nAmistad, NM 88410\u003C\u002Fp>\n\n\u003Cp>RE: 616186\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McDaniel and Ms. Shields:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that in July 2021 the U.S. Food and Drug Administration (FDA) reviewed your product labeling and your website at the Internet address www.mcdanielwater.com and has observed that you take orders there for the product “Black Indian Salve,” which you also refer to on your website as “Indian Herb,” “X,” and “Black Salve.” As explained further below, this product is an unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 301(d). You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Your “Black Indian Salve” is concerning from a public health perspective because it is labeled to contain the ingredients bloodroot (Sanguinaria canadensis) and zinc chloride. Both substances are known corrosive agents. The combination of bloodroot and zinc chloride results in a corrosive topical agent capable of indiscriminately damaging healthy and diseased tissue alike and forming eschar (sloughed dead tissue). The tissue necrosis caused by topical application of products containing such ingredients (often referred to as \"black salves\") is well-documented.\u003C\u002Fp>\n\n\u003Cp>On May 16, 2019, the FDA issued a warning letter to McDaniel Life-Line LLC which offered a similar product, “Indian Herb,” for sale directly to consumers. The agency advises you that on February 8, 2019, “Indian Herb” was the subject of a voluntary worldwide recall of all lots of the product that were within expiration. In addition, the FDA Center for Drug Evaluation and Research (CDER) issued a safety alert on February 12, 2019 concerning the potential safety hazard associated with “Indian Herb” (see Indian Herb FDA Alert).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You market “Black Indian Salve” as a dietary supplement with directions for both topical application and for ingestion. However, “Black Indian Salve” does not meet the definition of a dietary supplement under section 201(ff) of the FD&amp;C Act. Only products that are intended solely for ingestion may be lawfully marketed as dietary supplements. See section 201(ff)(2)(A)(i) of the FD&amp;C Act, 21 U.S.C. 321(ff)(2)(A)(i). Topical products and products intended to enter the body through the skin or mucosal tissues are not dietary supplements. Therefore, your “Black Indian Salve” is not a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>Rather, claims on your product labeling and your website establish that “Black Indian Salve” is a drug as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For to affect the structure or function of the body. Examples of claims on your product label and website that establish the intended use of your “Black Indian Salve” product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Black Indian Salve\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>From the package insert accompanying the product:\u003C\u002Fp>\n\n\u003Cp>• “The following guidelines are offered for the application of ‘The Black Indian Salve’ in treating various types of abnormal growths both external and internal. . . . This is how people have used the ‘Black Indian Salve’ on external growths . . . The ‘Black Indian Salve’ is tracing out the infected area and drawing the poison back into the nucleus. It will make a hard core, similar to the core of a boil – hard and rubbery. The redness will diminish and a white ring will begin to appear around the nucleus. . . . Between the fifth and seventh day, a white ring will start to separate from the healthy tissue and become very loose. . . . Usually after the second application the growth itself is dead. The growth will become more painful as the body begins to eject its dying tissue. Swelling often occurs. . . . The core will not come out unless the whole growth is dead and detached from the healthy tissue. Then and only then will it come out intact. There will be no need for surgery. . . . For most people, in about 10 days the body completely pushes out the dead growth and the fever disappears. . . During the next 10 days, or as long as it takes, the body will fill in the cavity with either healthy tissue or scar tissue, depending on the individual’s body chemistry and health. . . . In many cases of removing external growths, people report that even though large masses of tissue was ejected from the body, even to the point of revealing the muscle structure below, bleeding did not occur and the body completely filled in the area where the growth had been.”\u003C\u002Fp>\n\n\u003Cp>From the website http:\u002F\u002Fmcdanielwater.com\u002Fpage12.html:\u003C\u002Fp>\n\n\u003Cp>• “The Indian Herb is a 100-year-old folk remedy used to attack disease and aid in the healing process. It is also often referred to as ‘X’ or ‘Black Salve’. Indian Herb may be taken internally or applied externally to abnormal skin growths.”\u003Cbr>\n• “\u003Cstrong>Yellow Dock\u003C\u002Fstrong> contains iron and can improve the function of the liver, kidneys, lymph glands and intestines. It has been used for the treatment of jaundice . . ..”\u003Cbr>\n• “\u003Cstrong>Blood Root\u003C\u002Fstrong> is considered highly effective for skin conditions . . . Its primary alkaloid, sanguinarine, has been found to be a potent anti-cancer agent. It is prized for its ability to heal infections &amp; stimulate healthy tissue growth.”\u003Cbr>\n• “\u003Cstrong>Licorice Root\u003C\u002Fstrong> has been known to enhance immunity by boosting the level of interferon.”\u003Cbr>\n• “\u003Cstrong>Galangal\u003C\u002Fstrong> . . . In recent studies, it was also found to have anti-cancer activities. It acts as an anti-oxidant and suppresses the genotoxicity of chemicals. Genotoxic substances are known to be potentially mutagenic or potentially cancerous.”\u003C\u002Fp>\n\n\u003Cp>Your “Black Indian Salve” product is also a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in its labeling. Under section 505(a) of the FD&amp;C Act, a new drug may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA. There is no FDA-approved application in effect for your “Black Indian Salve.” Thus, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance, 10903 New Hampshire Avenue, WO51, Silver Spring, MD 20993-0002 by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCarolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGary McDaniel\u002FRuth Shields\n\nRecipient Title\n\nDirectors\n\nMcDaniel Water, LLC\n\n23711 Hix Drive\n\nCanyon, TX 79015\n\nUnited States\n\nmcdanielwater@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSeptember 7, 2021\n\nRuth Shields, Director\n\nMcDaniel Water LLC\n\n363 Ricketson Road\n\nAmistad, NM 88410\n\nRE: 616186\n\nDear Mr. McDaniel and Ms. Shields:\n\nThis letter is to advise you that in July 2021 the U.S. Food and Drug Administration (FDA) reviewed your product labeling and your website at the Internet address www.mcdanielwater.com and has observed that you take orders there for the product “Black Indian Salve,” which you also refer to on your website as “Indian Herb,” “X,” and “Black Salve.” As explained further below, this product is an unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 301(d). You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nYour “Black Indian Salve” is concerning from a public health perspective because it is labeled to contain the ingredients bloodroot (Sanguinaria canadensis) and zinc chloride. Both substances are known corrosive agents. The combination of bloodroot and zinc chloride results in a corrosive topical agent capable of indiscriminately damaging healthy and diseased tissue alike and forming eschar (sloughed dead tissue). The tissue necrosis caused by topical application of products containing such ingredients (often referred to as \"black salves\") is well-documented.\n\nOn May 16, 2019, the FDA issued a warning letter to McDaniel Life-Line LLC which offered a similar product, “Indian Herb,” for sale directly to consumers. The agency advises you that on February 8, 2019, “Indian Herb” was the subject of a voluntary worldwide recall of all lots of the product that were within expiration. In addition, the FDA Center for Drug Evaluation and Research (CDER) issued a safety alert on February 12, 2019 concerning the potential safety hazard associated with “Indian Herb” (see Indian Herb FDA Alert).\n\nUnapproved New Drug Violations\n\nYou market “Black Indian Salve” as a dietary supplement with directions for both topical application and for ingestion. However, “Black Indian Salve” does not meet the definition of a dietary supplement under section 201(ff) of the FD&C Act. Only products that are intended solely for ingestion may be lawfully marketed as dietary supplements. See section 201(ff)(2)(A)(i) of the FD&C Act, 21 U.S.C. 321(ff)(2)(A)(i). Topical products and products intended to enter the body through the skin or mucosal tissues are not dietary supplements. Therefore, your “Black Indian Salve” is not a dietary supplement.\n\nRather, claims on your product labeling and your website establish that “Black Indian Salve” is a drug as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For to affect the structure or function of the body. Examples of claims on your product label and website that establish the intended use of your “Black Indian Salve” product as a drug include, but may not be limited to, the following:\n\nBlack Indian Salve\n\nFrom the package insert accompanying the product:\n\n• “The following guidelines are offered for the application of ‘The Black Indian Salve’ in treating various types of abnormal growths both external and internal. . . . This is how people have used the ‘Black Indian Salve’ on external growths . . . The ‘Black Indian Salve’ is tracing out the infected area and drawing the poison back into the nucleus. It will make a hard core, similar to the core of a boil – hard and rubbery. The redness will diminish and a white ring will begin to appear around the nucleus. . . . Between the fifth and seventh day, a white ring will start to separate from the healthy tissue and become very loose. . . . Usually after the second application the growth itself is dead. The growth will become more painful as the body begins to eject its dying tissue. Swelling often occurs. . . . The core will not come out unless the whole growth is dead and detached from the healthy tissue. Then and only then will it come out intact. There will be no need for surgery. . . . For most people, in about 10 days the body completely pushes out the dead growth and the fever disappears. . . During the next 10 days, or as long as it takes, the body will fill in the cavity with either healthy tissue or scar tissue, depending on the individual’s body chemistry and health. . . . In many cases of removing external growths, people report that even though large masses of tissue was ejected from the body, even to the point of revealing the muscle structure below, bleeding did not occur and the body completely filled in the area where the growth had been.”\n\nFrom the website http:\u002F\u002Fmcdanielwater.com\u002Fpage12.html:\n\n• “The Indian Herb is a 100-year-old folk remedy used to attack disease and aid in the healing process. It is also often referred to as ‘X’ or ‘Black Salve’. Indian Herb may be taken internally or applied externally to abnormal skin growths.”\n\n• “Yellow Dock contains iron and can improve the function of the liver, kidneys, lymph glands and intestines. It has been used for the treatment of jaundice . . ..”\n\n• “Blood Root is considered highly effective for skin conditions . . . Its primary alkaloid, sanguinarine, has been found to be a potent anti-cancer agent. It is prized for its ability to heal infections & stimulate healthy tissue growth.”\n\n• “Licorice Root has been known to enhance immunity by boosting the level of interferon.”\n\n• “Galangal . . . In recent studies, it was also found to have anti-cancer activities. It acts as an anti-oxidant and suppresses the genotoxicity of chemicals. Genotoxic substances are known to be potentially mutagenic or potentially cancerous.”\n\nYour “Black Indian Salve” product is also a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in its labeling. Under section 505(a) of the FD&C Act, a new drug may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA. There is no FDA-approved application in effect for your “Black Indian Salve.” Thus, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance, 10903 New Hampshire Avenue, WO51, Silver Spring, MD 20993-0002 by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","McDaniel Water, LLC","mcdaniel-water-llc-616186-09072021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcdaniel-water-llc-616186-09072021","2026-10-26T08:09:22.205882+00:00","2021-09-14","616186","Gary McDaniel\u002FRuth Shields","2026-08-20T02:36:08.132+00:00","Via Email","2021-09-07",{"id":124,"raw":125,"subject":130,"body_html":131,"body_text":132,"firm_name":133,"letter_id":134,"created_at":114,"fei_number":20,"letter_url":135,"updated_at":136,"action_type":23,"case_status":24,"posted_date":137,"marcs_cms_no":138,"product_type":139,"closeout_date":20,"issuing_office":129,"recipient_name":140,"body_fetched_at":141,"delivery_method":142,"recipient_title":20,"reference_number":20,"action_taken_date":143,"medical_device_id":20,"response_letter_date":20},3005,[126,127,128,129,130,13,13,13],"\u003Ctime datetime=\"2021-11-30T14:20:00Z\">11\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-12T04:00:00Z\">05\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcelroy-imports-613680-05122021\">McElroy Imports\u003C\u002Fa>","Division of Northeast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Martin McElroy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>McElroy Imports\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>92 Wendy Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Glen Mills\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19342\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 613680\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McElroy:\u003C\u002Fp>\n\n\u003Cp>From January 27, 2021 to February 9, 2021, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of McElroy Imports located at 92 Wendy Lane, Glen Mills, PA 19342. We also conducted a FSVP inspection on June 11, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your Creamy Caramels with Sea Salt imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea Bags imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of both the initial FSVP inspection on June 11, 2019 and the follow-up inspection on February 9, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations.\u003Cbr>\n\u003Cbr>\nWe acknowledge your response email dated February 9, 2021. You stated that you would “advise \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your concern and get back to you asap along with the other companies.” During the inspection, you provided copies of an audit report titled BRCGS Food Safety, Certificate of Registration, NSF Certificate of Conformity, and an FDA Establishment Inspection Report from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also provided a SAI Global Certificate of Conformity for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the manufacturer of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not provide any documents regarding your foreign suppliers \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>, both located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We address your documents below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, or follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for each of the following foods:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea Bags imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>2. For Creamy Caramels with Sea Salt from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, although you provided documents regarding your foreign supplier, you did not meet your requirements to conduct a hazard analysis in accordance with 21 CFR 1.504, you did not evaluate your foreign supplier’s performance in accordance with 21 CFR 1.505, nor did you perform foreign supplier verification activities in accordance with 21 CFR 1.506. The BRCGS Food Safety audit refers to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hazard Analysis and Critical Control Point (HACCP) plan, but you did not provide the hazard analysis contained in the HACCP plan or document your review. You may meet your requirement to conduct a hazard analysis, as required under 21 CFR 1.504(a), by reviewing and assessing your supplier’s hazard analysis and documenting your review and assessment of that hazard analysis (21 CFR 1.504(d)). The FSVP regulation also generally requires that you evaluate your foreign supplier’s performance (21 CFR 1.505). You did not provide documentation of your evaluation of your foreign supplier’s performance. With respect to the requirements of 21 CFR 1.506, while you may rely on third party food safety audits as part of your foreign supplier verification activities, you must ensure the audit is performed by a qualified auditor and that they assessed compliance with FDA food safety regulations, as required by 1.506(e). You must also promptly review and assess any third-party audit that constitutes a verification activity, as well as document your review and assessment, among other requirements (21 CFR 1.506(e)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The above matters are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of food products you import that appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Pasquale Leone, Compliance Officer, Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Pasquale.Leone@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Leone via email at Pasquale.Leone@fda.hhs.gov. Please reference CMS # 613680 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dawne Hines\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMartin McElroy\n\nRecipient Title\n\nPresident\n\nMcElroy Imports\n\n92 Wendy Lane\n\nGlen Mills, PA 19342\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\nCMS # 613680\n\nDear Mr. McElroy:\n\nFrom January 27, 2021 to February 9, 2021, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of McElroy Imports located at 92 Wendy Lane, Glen Mills, PA 19342. We also conducted a FSVP inspection on June 11, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your Creamy Caramels with Sea Salt imported from (b)(4) located in (b)(4); (b)(4) Tea Bags imported from (b)(4) located in (b)(4); and (b)(4) imported from (b)(4) located in (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of both the initial FSVP inspection on June 11, 2019 and the follow-up inspection on February 9, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations.\n\nWe acknowledge your response email dated February 9, 2021. You stated that you would “advise (b)(4) of your concern and get back to you asap along with the other companies.” During the inspection, you provided copies of an audit report titled BRCGS Food Safety, Certificate of Registration, NSF Certificate of Conformity, and an FDA Establishment Inspection Report from your foreign supplier (b)(4). You also provided a SAI Global Certificate of Conformity for (b)(4), the manufacturer of (b)(4). You did not provide any documents regarding your foreign suppliers (b)(4) or (b)(4), both located in (b)(4). We address your documents below.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, or follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for each of the following foods:\n\n(b)(4) Tea Bags imported from (b)(4) located in (b)(4)\n\n(b)(4) imported from (b)(4) located in (b)(4)\n\n2. For Creamy Caramels with Sea Salt from your foreign supplier (b)(4), although you provided documents regarding your foreign supplier, you did not meet your requirements to conduct a hazard analysis in accordance with 21 CFR 1.504, you did not evaluate your foreign supplier’s performance in accordance with 21 CFR 1.505, nor did you perform foreign supplier verification activities in accordance with 21 CFR 1.506. The BRCGS Food Safety audit refers to (b)(4) Hazard Analysis and Critical Control Point (HACCP) plan, but you did not provide the hazard analysis contained in the HACCP plan or document your review. You may meet your requirement to conduct a hazard analysis, as required under 21 CFR 1.504(a), by reviewing and assessing your supplier’s hazard analysis and documenting your review and assessment of that hazard analysis (21 CFR 1.504(d)). The FSVP regulation also generally requires that you evaluate your foreign supplier’s performance (21 CFR 1.505). You did not provide documentation of your evaluation of your foreign supplier’s performance. With respect to the requirements of 21 CFR 1.506, while you may rely on third party food safety audits as part of your foreign supplier verification activities, you must ensure the audit is performed by a qualified auditor and that they assessed compliance with FDA food safety regulations, as required by 1.506(e). You must also promptly review and assess any third-party audit that constitutes a verification activity, as well as document your review and assessment, among other requirements (21 CFR 1.506(e)).\n\n(b)(3)(A)\n\nThe above matters are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of food products you import that appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Pasquale Leone, Compliance Officer, Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Pasquale.Leone@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Leone via email at Pasquale.Leone@fda.hhs.gov. Please reference CMS # 613680 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDawne Hines\n\nProgram Division Director\n\nDivision of Northeast Imports","McElroy Imports","mcelroy-imports-613680-05122021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcelroy-imports-613680-05122021","2026-10-26T08:09:22.240456+00:00","2021-11-30","613680","Food & Beverages","Martin McElroy","2026-08-20T02:23:05.647+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2021-05-12",{"id":145,"raw":146,"subject":39,"body_html":150,"body_text":151,"firm_name":152,"letter_id":153,"created_at":92,"fei_number":20,"letter_url":154,"updated_at":155,"action_type":23,"case_status":24,"posted_date":156,"marcs_cms_no":157,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":158,"body_fetched_at":159,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":156,"medical_device_id":20,"response_letter_date":20},2436,[147,148,149,38,39,13,13,13],"\u003Ctime datetime=\"2022-09-13T19:00:00Z\">09\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-13T04:00:00Z\">09\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fteam-mc-inc-dba-community-vapor-638702-09132022\">Team MC Inc. d\u002Fb\u002Fa Community Vapor\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Carolynn Clements\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Team MC Inc. d\u002Fb\u002Fa Community Vapor\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2466 Old Fort Pkwy\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Murfreesboro\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>37128-4163\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:communityvapor@outlook.com\"> communityvapor@outlook.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 13, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Clements:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Team MC Inc. d\u002Fb\u002Fa Community Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States COMMUNITY Vapor BLING BLING BERRY 120ML 12MG e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200620, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nCarolynn Clements\n\nRecipient Title\n\nOwner\n\nTeam MC Inc. d\u002Fb\u002Fa Community Vapor\n\n2466 Old Fort Pkwy\n\nMurfreesboro, TN 37128-4163\n\nUnited States\n\ncommunityvapor@outlook.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 13, 2022\n\nWARNING LETTER\n\nDear Ms. Clements:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Team MC Inc. d\u002Fb\u002Fa Community Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States COMMUNITY Vapor BLING BLING BERRY 120ML 12MG e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200620, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Team MC Inc. d\u002Fb\u002Fa Community Vapor","team-mc-inc-dba-community-vapor-638702-09132022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fteam-mc-inc-dba-community-vapor-638702-09132022","2026-10-26T08:10:10.229167+00:00","2022-09-13","638702","Carolynn Clements","2026-08-20T01:35:03.061+00:00",{"id":161,"raw":162,"subject":167,"body_html":169,"body_text":170,"firm_name":171,"letter_id":172,"created_at":44,"fei_number":20,"letter_url":173,"updated_at":174,"action_type":23,"case_status":70,"posted_date":175,"marcs_cms_no":176,"product_type":139,"closeout_date":177,"issuing_office":166,"recipient_name":178,"body_fetched_at":179,"delivery_method":78,"recipient_title":20,"reference_number":20,"action_taken_date":180,"medical_device_id":20,"response_letter_date":20},1412,[163,164,165,166,167,13,168,13],"\u003Ctime datetime=\"2024-06-18T13:20:00Z\">06\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-16T04:00:00Z\">05\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcclures-lancaster-old-fashioned-llc-670611-05162024\">McClure’s Lancaster Old Fashioned, LLC\u003C\u002Fa>","Division of Human and Animal Food Operations East II","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcclures-lancaster-old-fashioned-llc-670611-07212025\">\u003Ctime datetime=\"2025-07-28T04:00:00Z\">07\u002F28\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Thomas Keenan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner &amp; President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>McClure’s Lancaster Old Fashioned, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1212 Reading Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bowmansville\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 670611\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 16, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Keenan:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) bakery products manufacturing facility, located at 1212 Reading Road, Bowmansville, PA, 17507, from September 18 through October 3, 2023. During our inspection of your facility, the FDA found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP and PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the RTE sticky buns, pies, and cakes manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or may have been rendered injurious to health. The inspection also revealed that certain products manufactured in your facility are misbranded because, among other things, the labels for certain products declare the major food allergen of “peanut” as an ingredient which is not intentionally introduced in the formulation of those products, which is false or misleading.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP and PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP and PC rule through links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>On October 3, 2023, at the conclusion of the inspection, the FDA investigators issued your facility a Form FDA 483, Inspectional Observations. To date, we have not received your response to the Form FDA 483. Based on our review of the inspectional findings, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>1. You did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for each type of food manufactured, processed, packed, or held at your facility to determine whether there are any hazards requiring a preventive control, as required by 21 CFR § 117.130(a)(1). Although you have a written hazard analysis for your RTE creme-filled doughnuts, you told our investigator that you had not conducted a hazard analysis for your various RTE sticky buns, pies, and cakes. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You did not identify and evaluate \u003Cu>bacterial pathogens\u003C\u002Fu>, such as \u003Cem>Salmonella\u003C\u002Fem>, as a known or reasonably foreseeable hazard to determine whether bacterial pathogens are a hazard requiring a preventive control in your RTE sticky buns, pies, and cakes. For example, your facility manufactures RTE banana cream pie and chocolate peanut butter streusel, which contain eggs and wheat flour as ingredients. These ingredients have been associated with vegetative bacterial pathogens, such as \u003Cem>Salmonella\u003C\u002Fem> and pathogenic \u003Cem>E. coli\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify bacterial pathogens as a hazard requiring a preventive control. Preventive controls include process controls, which include procedures, practices, and processes to ensure the control of parameters during operations such as heat processing. Process controls must also include the parameters associated with the control of the hazard and the minimum and\u002For maximum values needed to significantly minimize or prevent the hazards (see 21 CFR § 117.135(c)(1)). Note that these controls must be validated as required by 21 CFR § 117.160.\u003C\u002Fp>\n\n\u003Cp>During the inspection, you told our investigator that you would conduct a hazard analysis for your sticky buns, pies, and cakes, as many of the hazards and mitigation strategies will be similar to those you identified for your creme-filled doughnuts. However, to date, you have not provided the hazard analysis for sticky buns, pies, and cakes.\u003C\u002Fp>\n\n\u003Cp>b. You did not identify and evaluate \u003Cu>recontamination with environmental pathogens\u003C\u002Fu> (e.g., \u003Cem>Salmonella\u003C\u002Fem> and \u003Cem>L. monocytogenes\u003C\u002Fem>) as a known or reasonably foreseeable hazard to determine whether recontamination with environmental pathogens is a hazard requiring a preventive control, to comply with 21 CFR § 117.130(c)(1)(ii). Your facility manufactures RTE bakery products (sticky buns, pies, and cakes) which are exposed to the environment after cooking, such as while they are cooled and prior to packaging. The packaged food does not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize the pathogen.\u003C\u002Fp>\n\n\u003Cp>A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control. For example, sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR § 117.135(c)(3)). In addition, note that environmental monitoring is required if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control (see 21 CFR § 117.165(a)(3)).\u003C\u002Fp>\n\n\u003Cp>Your hazard analysis for your doughnut products identifies recontamination with environmental pathogens as a hazard requiring a preventive control. You have an Environmental Monitoring Program (dated June 5, 2023) to verify your sanitation controls; however, you told our investigator that you had not implemented the Environmental Monitoring Program. Also, it is not clear if the areas in your bakery where you manufacture sticky buns, pies, and cakes were included in the program. Furthermore, your Environmental Monitoring Program does not identify the timing and frequency for collecting and testing the samples, identify the analytical tests to be conducted, or include the corrective action procedures, as required by 21 CFR § 117.165(b)(3)(iv), (v), and (vii).\u003C\u002Fp>\n\n\u003Cp>c. You did not identify and evaluate \u003Cu>allergens\u003C\u002Fu> as a known or reasonably foreseeable hazard to determine whether allergens are a hazard requiring a preventive control. Your facility manufactures various bakery products (sticky buns, pies, and cakes) that contain allergens (such as wheat, eggs, milk, soy, peanut, and tree nuts), and products containing different allergen profiles are processed on shared equipment and using shared utensils on the same production day. For example, you manufacture a banana cream pie (that contains wheat, eggs, milk, and soy) and a coconut cream pie (that contains wheat, eggs, milk, soy, and coconut) in the same area of the facility using the same equipment. You informed our investigator that it was your regular practice to produce products that contain different allergen profiles using shared utensils and equipment on the same production day.\u003C\u002Fp>\n\n\u003Cp>A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergens as a hazard requiring a preventive control. Food allergen controls include procedures, practices, and processes employed for ensuring protection of food from allergen cross-contact (including during storage, handling, and use) and for labeling to ensure that all food allergens required to be stated are included on the label (see 21 CFR § 117.135(c)(2)). Note that preventive controls are subject to preventive control management components (monitoring, verification and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR § 117.140).\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B)\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>2. Your equipment and utensils were not designed and were not of such material and workmanship to be adequately cleanable, and were not adequately maintained to protect against contamination, as required by 21 CFR § 117.40(a)(1). On September 20, 2023, the FDA Investigator observed production of Country Maid Creme Filled Doughnuts with Lot Code: 263 and noted duct tape at the joints of the grey PVC pipe which appeared uncleanable and was located directly above exposed creme inside the doughnut filler-hopper. You instructed your employees to remove the tape from the exterior areas of the PVC pipe, where our investigator observed numerous gouges which do not appear easily cleanable. This equipment is used to convey ready-to-eat creme to the filler-hoppers, which inject creme into your RTE doughnut products, after the fry step. During the inspection, you stated this equipment is only disassembled for cleaning and sanitation \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which can result in residual creme remaining on the equipment food contact surfaces for several days between production runs.\u003C\u002Fp>\n\n\u003Cp>During the inspection, you stated you would generate written cleaning procedures for the food contact surfaces of the RTE creme-filling equipment. You also indicated that you may consider replacing the PVC piping with stainless steel but did not commit to do so. To date, you have not provided any corrective actions or supporting documentation to demonstrate that you have adequately resolved this observation.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranding Violation:\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>3. Your Country Maid brand 6- Chocolate Creme Filled Doughnuts and the Country Maid brand 6- Creme Filled Doughnuts are misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] in that the labeling is false or misleading because “peanut” is declared in the “Contains” statements; however, “peanut” is not an ingredient in the formulations of these products. You stated that this was done as a mitigation strategy for the identified reasonably foreseeable hazard of “Allergen cross contamination.” However, FDA expects food manufacturers to follow the CGMP and PC rule to prevent the unintentional incorporation of allergens into foods which are not formulated to contain them. Labeling is not a substitute for adherence to the CGMP and PC rule. Instead, firms must comply with the applicable CGMP and PC requirements to address allergen cross-contact.\u003C\u002Fp>\n\n\u003Cp>4. Your Country Maid brand 6- Creme Filled Doughnuts, Country Maid brand 6- Chocolate Creme Filled Doughnuts and McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that:\u003Cbr>\na. The Country Maid brand 6- Creme Filled Doughnuts and Country Maid brand 6- Chocolate Creme Filled Doughnuts product ingredient labels fail to declare the appropriate common or usual name and the sub ingredients of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Flour, from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by 21 CFR § 101.4(b)(2).\u003Cbr>\nb. Your Country Maid brand 6- Chocolate Creme Filled Doughnuts ingredient listing states, in part: “[M]ay contain: soybean, cottonseed and\u002For palm oil; sugar, cocoa, whole eggs,” etc. which is not in accordance with 21 CFR § 101.4.\u003Cbr>\nc. The McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie ingredient label declares “shortening (soy &amp; palm)” but does not include the term “vegetable” preceding “shortening,” as required by 21 CFR § 101.4(b)(14).\u003C\u002Fp>\n\n\u003Cp>5. Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie, Country Maid brand 6- Chocolate Creme Filled Doughnuts and Country Maid brand 6- Creme Filled Doughnuts products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. § 343(q)] in that the nutrition facts information is not as defined in 21 CFR § 101.9. Specifically,\u003Cbr>\na. The Nutrition Facts label (NFL) on the McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie product does not use the correct format defined in 21 CFR § 101.9.\u003Cbr>\nb. The Country Maid brand 6- Chocolate Creme Filled Doughnuts and the Country Maid brand 6- Creme Filled Doughnuts products do not include an NFL and you do not appear to have filed for an exemption from the requirement by filing an annual filing for those products which may qualify under 21 CFR § 101.9(j)(18)(ii).\u003C\u002Fp>\n\n\u003Cp>6. Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie, Country Maid brand 6- Creme Filled Doughnuts and the Country Maid brand 6- Chocolate Creme Filled\u003Cbr>\nMcClure’s Lancaster Old Fashioned, LLC. dba TNT Bakery FEI: 3004388201 CMS: 670611 Page 5 of 7 pages\u003Cbr>\nDoughnuts products are misbranded within the meaning of section 403(k) of the Act [21 U.S.C. § 343(k)], because the products bear or contain chemical preservatives but do not bear labeling stating the function of the preservatives. Specifically:\u003Cbr>\na. Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie product contains the chemical preservatives potassium sorbate and TBHQ; however, the product fails to bear labeling stating a separate description of the preservative functions, e.g., “preservative,” “to retard spoilage,” “a mold inhibitor,” “to help protect flavor” or “to promote color retention,” in accordance with 21 CFR § 101.22(j).\u003Cbr>\nb. Your Country Maid brand 6- Creme Filled Doughnuts and the Country Maid brand 6- Chocolate Creme Filled Doughnuts products contain the preservatives calcium propionate and sodium propionate in the ingredient lists; however, the preservative functions are not declared.\u003C\u002Fp>\n\n\u003Cp>7. Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie, Country Maid brand 6- Creme Filled Doughnuts and the Country Maid brand 6- Chocolate Creme Filled Doughnuts products are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343(e)(1)] in that the product labels fail to include the place of business of the manufacturer, packer, or distributor, as required by 21 CFR § 101.5(a). Specifically, the McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie fails to list the street address, city, state, and ZIP code and the Country Maid brand 6- Creme Filled Doughnuts and the Country Maid brand 6- Chocolate Creme Filled Doughnuts fail to list the street address; however, the street address may be omitted if the firm is listed in the local city or telephone directory.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comments:\u003C\u002Fp>\n\n\u003Cp>• We reviewed the regulatory status of the ingredients declared on the labeling of your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie and McClure’s Bakery Lancaster Old Fashioned brand Chocolate Peanut Butter Streusel products, and the products bear or contain Partially Hydrogenated Oils (PHOs) (i.e., Partially Hydrogenated Palm Kernel oil, Cotton Seed Oil, or Soybean Oil), which, as discussed further below, are unapproved food additives. The regulations pertaining to food additives are located in 21 CFR Part 170.\u003C\u002Fp>\n\n\u003Cp>Any substance intentionally added to a food, such as a bakery product, must be used in accordance with a food additive regulation approving the substance for that use, unless the substance is deemed Generally Recognized as Safe (GRAS) among experts qualified by scientific training and experience to evaluate its safety (“qualified experts”) under the conditions of its intended use, or is otherwise exempt from the food additive definition in section 201(s) of the Act [21 U.S.C. § 321(s)].\u003C\u002Fp>\n\n\u003Cp>PHOs are the primary dietary source of industrially produced trans fatty acids (IP-TFA). On June 17, 2015, FDA issued its final determination that PHOs are no longer GRAS for any use in human food and set a compliance period of three years to allow industry time to either reformulate products without PHOs and\u002For submit a food additive petition to FDA to permit specific uses of PHOs. The agency established a general compliance date of June 18, 2018, and an extended compliance date of January 1, 2021, for foods manufactured with uses of PHOs for which a food additive petition was submitted before June 18, 2019. All of these compliance dates have now elapsed. Foods bearing or containing PHOs may be subject to enforcement action by FDA. See Final Determination Regarding Partially Hydrogenated Oils (Removing Trans Fat), https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-additives-petitions\u002Ffinal-determination-regarding-partially-hydrogenated-oils-removing-trans-fat.\u003C\u002Fp>\n\n\u003Cp>As explained above, the use of PHOs in your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie and McClure’s Bakery Lancaster Old Fashioned brand Chocolate Peanut Butter Streusel products is not GRAS. Further, FDA is not aware of any other exemption from the food additive definition that would apply to PHOs for use as an ingredient in your bakery products. Therefore, PHOs used in this manner are food additives under section 201(s) of the Act and are subject to the provisions of section 409 of the Act [21 U.S.C. § 348]. Under section 409, food additives are required to be approved by FDA for their intended uses prior to marketing.\u003C\u002Fp>\n\n\u003Cp>• Congress provided for the “Contains” statement as one mechanism to comply with the major food allergen labeling requirements in section 403(w) of the Act [21 U.S.C. § 343(w)]. We note that your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie label uses a “Contains” statement which includes Yellow #5, which is not a major food allergen.\u003C\u002Fp>\n\n\u003Cp>• Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie label lists the ingredient “F,D, &amp; C, Titanium Dioxide.” Titanium Dioxide is not a certified color and therefore FD&amp;C or alternatives to this designation are not part of the common or usual name of the color ingredient, titanium dioxide.\u003C\u002Fp>\n\n\u003Cp>• Your Country Maid brand 6- Chocolate Creme Filled Doughnuts label appears to be missing or contains inappropriately placed commas and\u002For parentheses. Specifically, the ingredient statement states, in part: “[M]ay contain: soybean, cottonseed and\u002For palm oil; sugar, cocoa, whole eggs,” etc. It is unclear what part of this statement is intended to be captured by the “may contain” portion of the statement. Fat and\u002For oil ingredients must be declared in accordance with 21 CFR § 101.4(b)(14).\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) working days of the receipt of this letter as to the specific steps you have taken to address the stated violations, including an explanation of each step being taken to identify violations and make corrections to prevent the recurrence of similar violations. In your response, you should include copies of related documentation, including revised procedures, photographs, results of tests you have conducted, and other useful information that would assist us in evaluating your corrections. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Compliance Officer Daniel W. Johnson at U.S. Food &amp; Drug Administration, 200 Chestnut St. Room 900 Philadelphia, Pennsylvania 19106. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have questions regarding this letter, please contact Daniel W. Johnson by telephone at (215)-717-3746 or by email at Daniel.Johnson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robin M. Rivers\u003Cbr>\nActing Program Division Director\u003Cbr>\nHuman &amp; Animal Food East, Division 2\u003Cbr>\nOffice of Regulatory Affairs\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nrobin.rivers@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Section 403(a)(1) of the Act [21 U.S.C § 343(a)(1)].\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Thomas Keenan\n\nRecipient Title\n\nOwner & President\n\nMcClure’s Lancaster Old Fashioned, LLC\n\n1212 Reading Road\n\nBowmansville, PA 17507\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nWARNING LETTER\n\nCMS # 670611\n\nMay 16, 2024\n\nDear Mr. Keenan:\n\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) bakery products manufacturing facility, located at 1212 Reading Road, Bowmansville, PA, 17507, from September 18 through October 3, 2023. During our inspection of your facility, the FDA found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP and PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\n\nBased on FDA’s inspectional findings, we have determined that the RTE sticky buns, pies, and cakes manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or may have been rendered injurious to health. The inspection also revealed that certain products manufactured in your facility are misbranded because, among other things, the labels for certain products declare the major food allergen of “peanut” as an ingredient which is not intentionally introduced in the formulation of those products, which is false or misleading.1 In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP and PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP and PC rule through links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nOn October 3, 2023, at the conclusion of the inspection, the FDA investigators issued your facility a Form FDA 483, Inspectional Observations. To date, we have not received your response to the Form FDA 483. Based on our review of the inspectional findings, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\n\n1. You did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for each type of food manufactured, processed, packed, or held at your facility to determine whether there are any hazards requiring a preventive control, as required by 21 CFR § 117.130(a)(1). Although you have a written hazard analysis for your RTE creme-filled doughnuts, you told our investigator that you had not conducted a hazard analysis for your various RTE sticky buns, pies, and cakes. Specifically:\n\na. You did not identify and evaluate bacterial pathogens, such as Salmonella, as a known or reasonably foreseeable hazard to determine whether bacterial pathogens are a hazard requiring a preventive control in your RTE sticky buns, pies, and cakes. For example, your facility manufactures RTE banana cream pie and chocolate peanut butter streusel, which contain eggs and wheat flour as ingredients. These ingredients have been associated with vegetative bacterial pathogens, such as Salmonella and pathogenic E. coli.\n\nA knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify bacterial pathogens as a hazard requiring a preventive control. Preventive controls include process controls, which include procedures, practices, and processes to ensure the control of parameters during operations such as heat processing. Process controls must also include the parameters associated with the control of the hazard and the minimum and\u002For maximum values needed to significantly minimize or prevent the hazards (see 21 CFR § 117.135(c)(1)). Note that these controls must be validated as required by 21 CFR § 117.160.\n\nDuring the inspection, you told our investigator that you would conduct a hazard analysis for your sticky buns, pies, and cakes, as many of the hazards and mitigation strategies will be similar to those you identified for your creme-filled doughnuts. However, to date, you have not provided the hazard analysis for sticky buns, pies, and cakes.\n\nb. You did not identify and evaluate recontamination with environmental pathogens (e.g., Salmonella and L. monocytogenes) as a known or reasonably foreseeable hazard to determine whether recontamination with environmental pathogens is a hazard requiring a preventive control, to comply with 21 CFR § 117.130(c)(1)(ii). Your facility manufactures RTE bakery products (sticky buns, pies, and cakes) which are exposed to the environment after cooking, such as while they are cooled and prior to packaging. The packaged food does not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize the pathogen.\n\nA knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control. For example, sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR § 117.135(c)(3)). In addition, note that environmental monitoring is required if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control (see 21 CFR § 117.165(a)(3)).\n\nYour hazard analysis for your doughnut products identifies recontamination with environmental pathogens as a hazard requiring a preventive control. You have an Environmental Monitoring Program (dated June 5, 2023) to verify your sanitation controls; however, you told our investigator that you had not implemented the Environmental Monitoring Program. Also, it is not clear if the areas in your bakery where you manufacture sticky buns, pies, and cakes were included in the program. Furthermore, your Environmental Monitoring Program does not identify the timing and frequency for collecting and testing the samples, identify the analytical tests to be conducted, or include the corrective action procedures, as required by 21 CFR § 117.165(b)(3)(iv), (v), and (vii).\n\nc. You did not identify and evaluate allergens as a known or reasonably foreseeable hazard to determine whether allergens are a hazard requiring a preventive control. Your facility manufactures various bakery products (sticky buns, pies, and cakes) that contain allergens (such as wheat, eggs, milk, soy, peanut, and tree nuts), and products containing different allergen profiles are processed on shared equipment and using shared utensils on the same production day. For example, you manufacture a banana cream pie (that contains wheat, eggs, milk, and soy) and a coconut cream pie (that contains wheat, eggs, milk, soy, and coconut) in the same area of the facility using the same equipment. You informed our investigator that it was your regular practice to produce products that contain different allergen profiles using shared utensils and equipment on the same production day.\n\nA knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergens as a hazard requiring a preventive control. Food allergen controls include procedures, practices, and processes employed for ensuring protection of food from allergen cross-contact (including during storage, handling, and use) and for labeling to ensure that all food allergens required to be stated are included on the label (see 21 CFR § 117.135(c)(2)). Note that preventive controls are subject to preventive control management components (monitoring, verification and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR § 117.140).\n\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B)\n\n2. Your equipment and utensils were not designed and were not of such material and workmanship to be adequately cleanable, and were not adequately maintained to protect against contamination, as required by 21 CFR § 117.40(a)(1). On September 20, 2023, the FDA Investigator observed production of Country Maid Creme Filled Doughnuts with Lot Code: 263 and noted duct tape at the joints of the grey PVC pipe which appeared uncleanable and was located directly above exposed creme inside the doughnut filler-hopper. You instructed your employees to remove the tape from the exterior areas of the PVC pipe, where our investigator observed numerous gouges which do not appear easily cleanable. This equipment is used to convey ready-to-eat creme to the filler-hoppers, which inject creme into your RTE doughnut products, after the fry step. During the inspection, you stated this equipment is only disassembled for cleaning and sanitation (b)(4), which can result in residual creme remaining on the equipment food contact surfaces for several days between production runs.\n\nDuring the inspection, you stated you would generate written cleaning procedures for the food contact surfaces of the RTE creme-filling equipment. You also indicated that you may consider replacing the PVC piping with stainless steel but did not commit to do so. To date, you have not provided any corrective actions or supporting documentation to demonstrate that you have adequately resolved this observation.\n\nMisbranding Violation:\n\n3. Your Country Maid brand 6- Chocolate Creme Filled Doughnuts and the Country Maid brand 6- Creme Filled Doughnuts are misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] in that the labeling is false or misleading because “peanut” is declared in the “Contains” statements; however, “peanut” is not an ingredient in the formulations of these products. You stated that this was done as a mitigation strategy for the identified reasonably foreseeable hazard of “Allergen cross contamination.” However, FDA expects food manufacturers to follow the CGMP and PC rule to prevent the unintentional incorporation of allergens into foods which are not formulated to contain them. Labeling is not a substitute for adherence to the CGMP and PC rule. Instead, firms must comply with the applicable CGMP and PC requirements to address allergen cross-contact.\n\n4. Your Country Maid brand 6- Creme Filled Doughnuts, Country Maid brand 6- Chocolate Creme Filled Doughnuts and McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that:\n\na. The Country Maid brand 6- Creme Filled Doughnuts and Country Maid brand 6- Chocolate Creme Filled Doughnuts product ingredient labels fail to declare the appropriate common or usual name and the sub ingredients of the (b)(4) Flour, from the (b)(4), as required by 21 CFR § 101.4(b)(2).\n\nb. Your Country Maid brand 6- Chocolate Creme Filled Doughnuts ingredient listing states, in part: “[M]ay contain: soybean, cottonseed and\u002For palm oil; sugar, cocoa, whole eggs,” etc. which is not in accordance with 21 CFR § 101.4.\n\nc. The McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie ingredient label declares “shortening (soy & palm)” but does not include the term “vegetable” preceding “shortening,” as required by 21 CFR § 101.4(b)(14).\n\n5. Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie, Country Maid brand 6- Chocolate Creme Filled Doughnuts and Country Maid brand 6- Creme Filled Doughnuts products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. § 343(q)] in that the nutrition facts information is not as defined in 21 CFR § 101.9. Specifically,\n\na. The Nutrition Facts label (NFL) on the McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie product does not use the correct format defined in 21 CFR § 101.9.\n\nb. The Country Maid brand 6- Chocolate Creme Filled Doughnuts and the Country Maid brand 6- Creme Filled Doughnuts products do not include an NFL and you do not appear to have filed for an exemption from the requirement by filing an annual filing for those products which may qualify under 21 CFR § 101.9(j)(18)(ii).\n\n6. Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie, Country Maid brand 6- Creme Filled Doughnuts and the Country Maid brand 6- Chocolate Creme Filled\n\nMcClure’s Lancaster Old Fashioned, LLC. dba TNT Bakery FEI: 3004388201 CMS: 670611 Page 5 of 7 pages\n\nDoughnuts products are misbranded within the meaning of section 403(k) of the Act [21 U.S.C. § 343(k)], because the products bear or contain chemical preservatives but do not bear labeling stating the function of the preservatives. Specifically:\n\na. Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie product contains the chemical preservatives potassium sorbate and TBHQ; however, the product fails to bear labeling stating a separate description of the preservative functions, e.g., “preservative,” “to retard spoilage,” “a mold inhibitor,” “to help protect flavor” or “to promote color retention,” in accordance with 21 CFR § 101.22(j).\n\nb. Your Country Maid brand 6- Creme Filled Doughnuts and the Country Maid brand 6- Chocolate Creme Filled Doughnuts products contain the preservatives calcium propionate and sodium propionate in the ingredient lists; however, the preservative functions are not declared.\n\n7. Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie, Country Maid brand 6- Creme Filled Doughnuts and the Country Maid brand 6- Chocolate Creme Filled Doughnuts products are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343(e)(1)] in that the product labels fail to include the place of business of the manufacturer, packer, or distributor, as required by 21 CFR § 101.5(a). Specifically, the McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie fails to list the street address, city, state, and ZIP code and the Country Maid brand 6- Creme Filled Doughnuts and the Country Maid brand 6- Chocolate Creme Filled Doughnuts fail to list the street address; however, the street address may be omitted if the firm is listed in the local city or telephone directory.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also offer the following comments:\n\n• We reviewed the regulatory status of the ingredients declared on the labeling of your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie and McClure’s Bakery Lancaster Old Fashioned brand Chocolate Peanut Butter Streusel products, and the products bear or contain Partially Hydrogenated Oils (PHOs) (i.e., Partially Hydrogenated Palm Kernel oil, Cotton Seed Oil, or Soybean Oil), which, as discussed further below, are unapproved food additives. The regulations pertaining to food additives are located in 21 CFR Part 170.\n\nAny substance intentionally added to a food, such as a bakery product, must be used in accordance with a food additive regulation approving the substance for that use, unless the substance is deemed Generally Recognized as Safe (GRAS) among experts qualified by scientific training and experience to evaluate its safety (“qualified experts”) under the conditions of its intended use, or is otherwise exempt from the food additive definition in section 201(s) of the Act [21 U.S.C. § 321(s)].\n\nPHOs are the primary dietary source of industrially produced trans fatty acids (IP-TFA). On June 17, 2015, FDA issued its final determination that PHOs are no longer GRAS for any use in human food and set a compliance period of three years to allow industry time to either reformulate products without PHOs and\u002For submit a food additive petition to FDA to permit specific uses of PHOs. The agency established a general compliance date of June 18, 2018, and an extended compliance date of January 1, 2021, for foods manufactured with uses of PHOs for which a food additive petition was submitted before June 18, 2019. All of these compliance dates have now elapsed. Foods bearing or containing PHOs may be subject to enforcement action by FDA. See Final Determination Regarding Partially Hydrogenated Oils (Removing Trans Fat), https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-additives-petitions\u002Ffinal-determination-regarding-partially-hydrogenated-oils-removing-trans-fat.\n\nAs explained above, the use of PHOs in your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie and McClure’s Bakery Lancaster Old Fashioned brand Chocolate Peanut Butter Streusel products is not GRAS. Further, FDA is not aware of any other exemption from the food additive definition that would apply to PHOs for use as an ingredient in your bakery products. Therefore, PHOs used in this manner are food additives under section 201(s) of the Act and are subject to the provisions of section 409 of the Act [21 U.S.C. § 348]. Under section 409, food additives are required to be approved by FDA for their intended uses prior to marketing.\n\n• Congress provided for the “Contains” statement as one mechanism to comply with the major food allergen labeling requirements in section 403(w) of the Act [21 U.S.C. § 343(w)]. We note that your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie label uses a “Contains” statement which includes Yellow #5, which is not a major food allergen.\n\n• Your McClure’s Bakery Lancaster Old Fashioned brand Coconut Cream Pie label lists the ingredient “F,D, & C, Titanium Dioxide.” Titanium Dioxide is not a certified color and therefore FD&C or alternatives to this designation are not part of the common or usual name of the color ingredient, titanium dioxide.\n\n• Your Country Maid brand 6- Chocolate Creme Filled Doughnuts label appears to be missing or contains inappropriately placed commas and\u002For parentheses. Specifically, the ingredient statement states, in part: “[M]ay contain: soybean, cottonseed and\u002For palm oil; sugar, cocoa, whole eggs,” etc. It is unclear what part of this statement is intended to be captured by the “may contain” portion of the statement. Fat and\u002For oil ingredients must be declared in accordance with 21 CFR § 101.4(b)(14).\n\nPlease notify this office in writing within fifteen (15) working days of the receipt of this letter as to the specific steps you have taken to address the stated violations, including an explanation of each step being taken to identify violations and make corrections to prevent the recurrence of similar violations. In your response, you should include copies of related documentation, including revised procedures, photographs, results of tests you have conducted, and other useful information that would assist us in evaluating your corrections. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to Compliance Officer Daniel W. Johnson at U.S. Food & Drug Administration, 200 Chestnut St. Room 900 Philadelphia, Pennsylvania 19106. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have questions regarding this letter, please contact Daniel W. Johnson by telephone at (215)-717-3746 or by email at Daniel.Johnson@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRobin M. Rivers\n\nActing Program Division Director\n\nHuman & Animal Food East, Division 2\n\nOffice of Regulatory Affairs\n\nU.S. Food and Drug Administration\n\nrobin.rivers@fda.hhs.gov\n\n_____________________\n\n1 See Section 403(a)(1) of the Act [21 U.S.C § 343(a)(1)].","McClure’s Lancaster Old Fashioned, LLC","mcclures-lancaster-old-fashioned-llc-670611-05162024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmcclures-lancaster-old-fashioned-llc-670611-05162024","2026-10-26T08:09:22.092446+00:00","2024-06-18","670611","2025-07-28","Mr. Thomas Keenan","2026-08-20T00:01:48.639+00:00","2024-05-16",{"id":182,"raw":183,"subject":39,"body_html":187,"body_text":188,"firm_name":189,"letter_id":190,"created_at":19,"fei_number":20,"letter_url":191,"updated_at":192,"action_type":23,"case_status":24,"posted_date":193,"marcs_cms_no":194,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":195,"body_fetched_at":196,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":193,"medical_device_id":20,"response_letter_date":20},2898,[184,185,186,38,39,13,13,13],"\u003Ctime datetime=\"2022-01-31T20:00:00Z\">01\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-31T05:00:00Z\">01\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjdvapour-llc-dba-mcvapour-e-cigs-novelties-625771-01312022\">JDVapour LLC d\u002Fb\u002Fa McVapour E-Cig’s &amp; Novelties \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Darris McHargue\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>JDVapour LLC d\u002Fb\u002Fa McVapour E-Cig’s &amp; Novelties \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>340 South Andover Road, Suite D\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Andover\u003C\u002Fspan>, \u003Cspan>KS\u003C\u002Fspan> \u003Cspan>67002\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Mcvapourjd@gmail.com\"> Mcvapourjd@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 31, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McHargue:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that JDVapour LLC d\u002Fb\u002Fa McVapour ECig’s &amp; Novelties manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States McVapour Spearmint 6MG 50ML e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331k). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 5,800 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0001230, on September 8, 2020. However, FDA issued a negative action for STN PM0001230 in the form of a Marketing Denial Order determination on September 8, 2021, which covers 3,600 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0001230 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200447, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDarris McHargue\n\nRecipient Title\n\nOwner\n\nJDVapour LLC d\u002Fb\u002Fa McVapour E-Cig’s & Novelties\n\n340 South Andover Road, Suite D\n\nAndover, KS 67002\n\nUnited States\n\nMcvapourjd@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJanuary 31, 2022\n\nWARNING LETTER\n\nDear Mr. McHargue:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that JDVapour LLC d\u002Fb\u002Fa McVapour ECig’s & Novelties manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States McVapour Spearmint 6MG 50ML e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331k). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 5,800 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0001230, on September 8, 2020. However, FDA issued a negative action for STN PM0001230 in the form of a Marketing Denial Order determination on September 8, 2021, which covers 3,600 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0001230 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200447, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","JDVapour LLC d\u002Fb\u002Fa McVapour E-Cig’s & Novelties","jdvapour-llc-dba-mcvapour-e-cigs-novelties-625771-01312022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjdvapour-llc-dba-mcvapour-e-cigs-novelties-625771-01312022","2026-10-26T08:09:03.477977+00:00","2022-01-31","625771","Darris McHargue","2026-08-20T02:13:59.631+00:00",{"id":198,"raw":199,"subject":39,"body_html":203,"body_text":204,"firm_name":205,"letter_id":206,"created_at":19,"fei_number":20,"letter_url":207,"updated_at":208,"action_type":23,"case_status":24,"posted_date":209,"marcs_cms_no":210,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":211,"body_fetched_at":212,"delivery_method":51,"recipient_title":20,"reference_number":20,"action_taken_date":209,"medical_device_id":20,"response_letter_date":20},2619,[200,201,202,38,39,13,13,13],"\u003Ctime datetime=\"2022-06-23T19:00:00Z\">06\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-23T04:00:00Z\">06\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmccraney-enterprises-corporation-dba-vapors-heaven-634499-06232022\">McCraney Enterprises Corporation d\u002Fb\u002Fa Vapors Heaven    \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tammy Slaton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>McCraney Enterprises Corporation d\u002Fb\u002Fa Vapors Heaven    \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14391 Highway 43\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Russellville\u003C\u002Fspan>, \u003Cspan>AL\u003C\u002Fspan> \u003Cspan>35653\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Tmccraney14@gmail.com\"> Tmccraney14@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 23, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Slaton:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that McCraney Enterprises Corp. d\u002Fb\u002Fa Vapors Heaven manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Vapors Heaven Sweet Milk 3ml nic 120ml e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 100 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003851, on September 4, 2020. However, FDA issued a negative action for STN PM0003851 in the form of a Refuse To Accept determination on February 25, 2022, which covers 122 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by STN PM0003851 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200558, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nTammy Slaton\n\nRecipient Title\n\nOwner\n\nMcCraney Enterprises Corporation d\u002Fb\u002Fa Vapors Heaven\n\n14391 Highway 43\n\nRussellville, AL 35653\n\nUnited States\n\nTmccraney14@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 23, 2022\n\nWARNING LETTER\n\nDear Ms. Slaton:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that McCraney Enterprises Corp. d\u002Fb\u002Fa Vapors Heaven manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Vapors Heaven Sweet Milk 3ml nic 120ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 100 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003851, on September 4, 2020. However, FDA issued a negative action for STN PM0003851 in the form of a Refuse To Accept determination on February 25, 2022, which covers 122 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by STN PM0003851 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200558, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","McCraney Enterprises Corporation d\u002Fb\u002Fa Vapors Heaven","mccraney-enterprises-corporation-dba-vapors-heaven-634499-06232022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmccraney-enterprises-corporation-dba-vapors-heaven-634499-06232022","2026-10-26T08:09:22.170713+00:00","2022-06-23","634499","Tammy Slaton","2026-08-20T01:49:45.469+00:00",10,{"510k":215,"classification":216,"enforcement":217,"event":218,"event_backfill":219,"pma":220,"warning_letter":221},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]